Document and Entity Information
Document and Entity Information - USD ($) | 12 Months Ended | ||
Dec. 31, 2022 | Mar. 19, 2023 | Jun. 30, 2022 | |
Document and Entity Information | |||
Document Type | 10-K | ||
Document Annual Report | true | ||
Document Period End Date | Dec. 31, 2022 | ||
Document Transition Report | false | ||
Entity Registrant Name | ZURA BIO LIMITED | ||
Entity Incorporation, State or Country Code | E9 | ||
Entity File Number | 001-40598 | ||
Entity Tax Identification Number | 00-0000000 | ||
Entity Address, Address Line One | 4225 Executive Square, Suite 600 | ||
Entity Address, City or Town | La Jolla | ||
Entity Address State Or Province | CA | ||
Entity Address, Postal Zip Code | 92037 | ||
City Area Code | 858 | ||
Local Phone Number | 247-0520 | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Small Business | true | ||
Entity Emerging Growth Company | true | ||
Entity Ex Transition Period | false | ||
ICFR Auditor Attestation Flag | false | ||
Entity Shell Company | true | ||
Entity Public Float | $ 137,310,000 | ||
Entity Common Stock, Shares Outstanding | 5,138,978 | ||
Auditor Name | Marcum LLP | ||
Auditor Firm ID | 688 | ||
Auditor Location | New York, NY | ||
Entity Central Index Key | 0001855644 | ||
Current Fiscal Year End Date | --12-31 | ||
Document Fiscal Year Focus | 2022 | ||
Document Fiscal Period Focus | FY | ||
Amendment Flag | false | ||
Warrants | |||
Document and Entity Information | |||
Title of 12(b) Security | Warrants | ||
Trading Symbol | ZURAW | ||
Security Exchange Name | NASDAQ | ||
Class A Ordinary shares | |||
Document and Entity Information | |||
Title of 12(b) Security | Class A Ordinary Shares | ||
Trading Symbol | ZURA | ||
Security Exchange Name | NASDAQ |
CONSOLIDATED BALANCES SHEET
CONSOLIDATED BALANCES SHEET - USD ($) | Dec. 31, 2022 | Dec. 31, 2021 |
Current assets: | ||
Cash | $ 13,785 | $ 729,223 |
Prepaid expenses | 19,702 | 422,894 |
Total current assets | 33,487 | 1,152,117 |
Investments held in Trust Account | 141,474,352 | 139,399,054 |
Total Assets | 141,507,839 | 140,551,171 |
Current liabilities: | ||
Accounts payable | 282,127 | 69,855 |
Accounts payable - related party | 78,893 | 2,872 |
Accrued expenses | 1,111,618 | 199,565 |
Note Payable - related party | 355,595 | |
Total current liabilities | 1,828,233 | 272,292 |
Deferred underwriting commissions | 4,010,000 | 4,010,000 |
Derivative warrant liabilities | 1,921,500 | 6,069,900 |
Total Liabilities | 7,759,733 | 10,352,192 |
Commitments and Contingencies | ||
Class A ordinary shares subject to possible redemption; 13,800,000 shares subject to possible redemption at $10.16 and $10.10 per share as of December 31, 2022 and December 31, 2021, respectively | 141,374,352 | 139,380,000 |
Shareholders' Deficit: | ||
Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding at December 31, 2022 and December 31, 2021 | ||
Accumulated deficit | (7,626,591) | (9,181,366) |
Total shareholders' deficit | (7,626,246) | (9,181,021) |
Total Liabilities, Class A Ordinary Shares Subject to Possible Redemption and Shareholders' Deficit | 141,507,839 | 140,551,171 |
Class A ordinary shares subject to possible redemption | ||
Current liabilities: | ||
Class A ordinary shares subject to possible redemption; 13,800,000 shares subject to possible redemption at $10.16 and $10.10 per share as of December 31, 2022 and December 31, 2021, respectively | 141,374,352 | 139,380,000 |
Class A Ordinary shares | ||
Shareholders' Deficit: | ||
Common Stock, Value | ||
Class B Ordinary shares | ||
Shareholders' Deficit: | ||
Common Stock, Value | $ 345 | $ 345 |
CONSOLIDATED BALANCES SHEET (Pa
CONSOLIDATED BALANCES SHEET (Parenthetical) - $ / shares | Dec. 31, 2022 | Dec. 31, 2021 |
Preference shares, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized | 1,000,000 | 1,000,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Class A ordinary shares subject to possible redemption | ||
Class A common stock subject to possible redemption, outstanding (in shares) | 13,800,000 | 13,800,000 |
Class A ordinary shares subject to possible redemption, redemption price (in dollars per share) | $ 10.16 | $ 10.10 |
Class A Ordinary shares | ||
Class A common stock subject to possible redemption, outstanding (in shares) | 13,800,000 | |
Ordinary shares, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Ordinary shares, shares authorized | 200,000,000 | 200,000,000 |
Class A common stock not subject to possible redemption | ||
Ordinary shares, shares issued | 0 | 0 |
Number of shares outstanding | 0 | 0 |
Class B Ordinary shares | ||
Ordinary shares, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Ordinary shares, shares authorized | 20,000,000 | 20,000,000 |
Ordinary shares, shares issued | 3,450,000 | 3,450,000 |
Number of shares outstanding | 3,450,000 | 3,450,000 |
CONSOLIDATED STATEMENTS OF OPER
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) | 10 Months Ended | 12 Months Ended |
Dec. 31, 2021 | Dec. 31, 2022 | |
General and administrative expenses | $ 720,696 | $ 2,294,039 |
General and administrative expenses - related party | 167,849 | 381,102 |
Loss from operations | (888,545) | (2,675,141) |
Other income / (loss) | ||
Loss upon issuance of private placement warrants | 1,773,000 | |
Income from investments held in Trust Account | 19,054 | 2,075,298 |
Change in fair value of derivative warrant liabilities | (10,238,100) | (4,148,400) |
Interest income on operating account | 51 | 570 |
Offering costs associated with derivative warrant liabilities | (747,015) | |
Total other income | 7,737,190 | 6,224,268 |
Net Income | $ 6,848,645 | $ 3,549,127 |
Class A Ordinary shares | ||
Other income / (loss) | ||
Weighted average number of common shares outstanding - basic | 7,834,343 | 13,800,000 |
Weighted average number of common shares outstanding - diluted | 7,834,343 | 13,800,000 |
Basic net income per ordinary shares | $ 0.62 | $ 0.21 |
Diluted net income per ordinary shares | $ 0.61 | $ 0.21 |
Class B Ordinary shares | ||
Other income / (loss) | ||
Weighted average number of common shares outstanding - basic | 3,130,303 | 3,450,000 |
Weighted average number of common shares outstanding - diluted | 3,310,606 | 3,450,000 |
Basic net income per ordinary shares | $ 0.62 | $ 0.21 |
Diluted net income per ordinary shares | $ 0.61 | $ 0.21 |
CONSOLIDATED STATEMENTS OF CHAN
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' DEFICIT - USD ($) | Class A Ordinary shares Ordinary Shares | Class B Ordinary shares Ordinary Shares | Additional Paid-in Capital | Accumulated Deficit | Total |
Balance at the beginning at Mar. 09, 2021 | $ 0 | $ 0 | $ 0 | $ 0 | $ 0 |
Balance at the beginning (in shares) at Mar. 09, 2021 | 0 | 0 | |||
CHANGES IN SHAREHOLDERS' DEFICIT | |||||
Issuance of Class B ordinary shares to Sponsor | $ 345 | 24,655 | 0 | 25,000 | |
Issuance of Class B ordinary shares to Sponsor (in shares) | 3,450,000 | ||||
Deemed capital contribution by Sponsor (restated) | 4,738,051 | 0 | 4,738,051 | ||
Fair value adjustment to Class A ordinary share redemption amount (restated) | (4,762,706) | (16,030,011) | (20,792,717) | ||
Net income | 0 | 6,848,645 | 6,848,645 | ||
Balance at the end at Dec. 31, 2021 | $ 345 | $ 0 | (9,181,366) | (9,181,021) | |
Balance at the end (in shares) at Dec. 31, 2021 | 3,450,000 | ||||
CHANGES IN SHAREHOLDERS' DEFICIT | |||||
Increase in redemption value of Class A ordinary shares subject to possible redemption | (1,994,352) | (1,994,352) | |||
Net income | 3,549,127 | 3,549,127 | |||
Balance at the end at Dec. 31, 2022 | $ 345 | $ (7,626,591) | $ (7,626,246) | ||
Balance at the end (in shares) at Dec. 31, 2022 | 3,450,000 |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) | 10 Months Ended | 12 Months Ended |
Dec. 31, 2021 | Dec. 31, 2022 | |
Cash Flows from Operating Activities: | ||
Net income | $ 6,848,645 | $ 3,549,127 |
Adjustments to reconcile net income to net cash used in operating activities: | ||
Change in fair value of derivative warrant liabilities | (10,238,100) | (4,148,400) |
Income from investments held in the Trust Account | (19,054) | (2,075,298) |
Offering costs associated with warrants | 747,015 | |
Loss upon issuance of private placement warrants | 1,773,000 | |
General and administrative expenses paid by related parties | 25,950 | |
Changes in operating assets and liabilities: | ||
Prepaid expenses | (422,894) | 403,192 |
Due form related party | 2,872 | |
Accounts payable | 69,855 | 212,272 |
Accounts payable - related party | 76,021 | |
Accrued expenses | 114,565 | 912,053 |
Net cash used in operating activities | (1,098,146) | (1,071,033) |
Cash Flows from Investing Activities | ||
Cash deposited in Trust Account | (139,380,000) | |
Net cash used in investing activities | (139,380,000) | |
Cash Flows from Financing Activities: | ||
Cash deposited in Trust Account | 25,000 | |
Proceeds received from note payable | (117,381) | 355,595 |
Proceeds from issuance of Class B ordinary share to Sponsor | 138,000,000 | |
Proceeds received from private placement | 5,910,000 | |
Reimbursement from underwriter | 480,000 | |
Offering costs paid | (3,090,250) | |
Net cash provided by financing activities | 141,207,369 | 355,595 |
Net change in cash | 729,223 | (715,438) |
Cash - beginning of the period | 0 | 729,223 |
Cash - end of the period | 729,223 | 13,785 |
Supplemental disclosure of non-cash investing and financing activities: | ||
Offering costs included in accrued expenses | 85,000 | |
Offering costs paid by related party under promissory note | 91,431 | |
Deferred underwriting commissions | 4,010,000 | |
Fair value adjustment to Class A ordinary shares subject to redemption | $ 20,792,717 | |
Increase in redemption value of Class A common stock subject to possible redemption | $ 1,994,352 |
DESCRIPTION OF ORGANIZATION, BU
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | 12 Months Ended |
Dec. 31, 2022 | |
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | |
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | NOTE 1. DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION Zura Bio Ltd., formerly known as JATT Acquisition Corp (the “Company”) was a blank check company incorporated as a Cayman Islands exempted company on March 10, 2021. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses that the Company has not yet identified (“Business Combination”). As of December 31, 2022, the Company had not yet commenced operations. All activity for the period from March 10, 2021 (inception) through December 31, 2022, relates to the Company’s formation and the initial public offering (the “Initial Public Offering”), which is described below, and since the Initial Public Offering the search for a Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company generates non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering. The Company has selected December 31 as its fiscal year end. The Company’s sponsor is JATT Ventures, L.P., a Cayman Islands exempted limited partnership (the “Sponsor”). The registration statement for the Company’s Initial Public Offering was declared effective on July 13, 2021. On July 16, 2021, the Company consummated its Initial Public Offering of 12,000,000 units (the “Units” and, with respect to the Class A ordinary shares included in the Units being offered, the “Public Shares”), at $10.00 per Unit, generating gross proceeds of $120.0 million, and incurring offering costs of approximately $10.5 million (net of reimbursement from underwriter of $480,000), of which approximately $3.4 million was for deferred underwriting commissions (see Note 5), approximately $4.7 million was incentives provided to Anchor Investors by the Sponsor (see Note 4), and approximately $685,000 of offering costs allocated to derivative warrant liabilities. On July 19, 2021, the underwriters fully exercised their option and purchased 1,800,000 additional Units, generating gross proceeds of $18.0 million (the “Over-Allotment”), and incurring offering costs of $990,000, of which $630,000 was for deferred underwriting commissions and approximately $62,000 was allocated to derivative warrant liabilities. Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (“Private Placement”) of 5,370,000 warrants (each, a “Private Placement Warrant” and collectively, the “Private Placement Warrants”), at a price of $1.00 per Private Placement Warrant to the Sponsor, generating proceeds of approximately $5.4 million (see Note 4). Concurrent with the consummation of the Over-Allotment on July 19, 2021, the Sponsor purchased 540,000 additional Private Placement Warrants, generating proceeds of $540,000 (the “Second Private Placement”). Upon the closing of the Initial Public Offering and the Private Placement on July 16, 2021, and the Over-Allotment and Second Private Placement on July 16, 2021, approximately $139.4 million ($10.10 per Unit) of the net proceeds were placed in a trust account (“Trust Account”) with Continental Stock Transfer & Trust Company acting as trustee and invested in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under Investment Company Act of 1940, as amended, (the “Investment Company Act”), which invest only in direct U.S. government treasury obligations, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the Trust Account as described below. The Company’s management has broad discretion with respect to the specific application of the net proceeds of its Initial Public Offering and the sale of Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. The Company’s initial Business Combination must be with one or more operating businesses or assets with a fair market value equal to at least 80% of the net assets held in the Trust Account (excluding any deferred underwriters fees and taxes payable on the income earned on the Trust Account) at the time the Company signs a definitive agreement in connection with the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. The Company will provide its holders of the Public Shares (the “Public Shareholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a general meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially at $10.10 per share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). The per-share amount to be distributed to Public Shareholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 5). These Public Shares have been recorded at a redemption value and classified as temporary equity in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity” (“ASC 480”). In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and a majority of the shares voted are voted in favor of the Business Combination. If a shareholder vote is not required by law and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to the amended and restated memorandum and articles of association which were adopted by the Company upon the consummation of the Initial Public Offering (the “amended and restated memorandum and articles of association”), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (the “SEC”), and file tender offer documents with the SEC prior to completing a Business Combination. If, however, a shareholder approval of the transactions is required by law, or the Company decides to obtain shareholder approval for business or legal reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each Public Shareholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction. If the Company seeks shareholder approval in connection with a Business Combination, the holders of the Founder Shares prior to this Initial Public Offering (the “Initial Shareholders”) have agreed to vote their Founder Shares (as defined in Note 4) and any Public Shares purchased during or after the Initial Public Offering in favor of a Business Combination. In addition, the Initial Shareholders agreed to waive their redemption rights with respect to their Founder Shares and Public Shares in connection with the completion of a Business Combination. In addition, the Company agreed not to enter into a definitive agreement regarding an initial Business Combination without the prior consent of the Sponsor. Notwithstanding the foregoing, the Company’s amended and restated memorandum and articles of association provides that a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the Class A ordinary shares sold in the Initial Public Offering, without the prior consent of the Company. The Company’s Sponsor, officers and directors have agreed not to propose an amendment to the Company’s amended and restated memorandum and articles of association that would affect the substance or timing of the Company’s obligation to provide for the redemption of its Public Shares in connection with a Business Combination or to redeem 100% of its Public Shares if the Company does not complete a Business Combination, unless the Company provides the Public Shareholders with the opportunity to redeem their Class A ordinary shares in conjunction with any such amendment. If the Company is unable to complete a Business Combination by April 17, 2023 (the “Combination Period”), the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten In connection with the redemption of 100% of the Company’s outstanding Public Shares for a portion of the funds held in the Trust Account, each holder will receive a full pro rata portion of the amount then in the Trust Account, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay the Company’s taxes payable (less up to $100,000 of interest to pay dissolution expenses). The Initial Shareholders agreed to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Initial Shareholders should acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters agreed to waive their rights to their deferred underwriting commission (see Note 5) held in the Trust Account in the event the Company does not complete a Business Combination within in the Combination Period, and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Company’s Public Shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be only $10.10 per share initially held in the Trust Account. In order to protect the amounts held in the Trust Account, the Sponsor agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into a written letter of intent, confidentiality or other similar agreement or business combination agreement, reduce the amount of funds in the Trust Account to below the lesser of (i) $10.10 per Public Share and (ii) the actual amount per Public Share held in the trust account as of the date of the liquidation of the Trust Account, if less than $10.10 per share due to reductions in the value of the trust assets, less taxes payable; provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the Trust Account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have vendors, service providers (except the Company’s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. Trust Account Redemptions and Extension of Combination Period On January 12, 2023, the Company held an extraordinary general shareholders meeting to vote upon a charter amendment to extend the time to complete a Business Combination until April 17, 2023 (the “Extension Amendment”). The shareholders approved the Extension Amendment. As a result of the approval of the Extension Amendment, the Sponsor (or one or more of its affiliates, members or third-party designees) has made a deposit into the Trust Account in the amount of $101,339, which was the lesser of (a) $200,000 or (b) $0.06 for each Public Share that was not redeemed in connection with the extraordinary general meeting, in exchange for an unsecured promissory note issued by the Company to the Sponsor. Also in connection with the Extension Amendment, holders of Public Shares elected to redeem 12,111,022 Class A ordinary shares, at a redemption price of $10.257 per share, for an aggregate redemption amount of approximately $124.2 million. Following such redemptions, approximately $17.4 million remains in the Trust Account, including the extension payment made by the Sponsor into the Trust Account of $101,339, and 1,688,978 Public Shares remain outstanding. Business Combination On March 20, 2023 (the “Closing Date”), Zura Bio Limited, a limited company incorporated under the laws of England and Wales (“Zura”), JATT Acquisition Corp, a Cayman Islands exempted company (“JATT”), JATT Merger Sub, a Cayman Islands exempted company and wholly owned subsidiary of JATT (“Merger Sub”), JATT Merger Sub 2, a Cayman Islands exempted company and wholly owned subsidiary of JATT (“Merger Sub 2”) and Zura Bio Holdings Ltd, a Cayman Islands exempted company (“Holdco”), consummated the closing of the transactions contemplated by the Business Combination Agreement, dated June 16, 2022, as amended on September 20, 2022, November 14, 2022 and January 13, 2023, by and among Zura, JATT, Merger Sub, Merger Sub 2, and Holdco (the “Business Combination Agreement”), following the approval at an extraordinary general meeting of JATT’s shareholders held on March 16, 2023 (the “Extraordinary General Meeting” and the consummation of such transactions, the “Closing”). Pursuant to the Business Combination Agreement, (i) Merger Sub merged with and into Holdco, with Holdco continuing as the surviving company and a wholly owned subsidiary of JATT (the “Merger”); (ii) immediately following the Merger, Holdco merged with and into Merger Sub 2, with Merger Sub 2 continuing as the surviving company and a wholly owned subsidiary of JATT (the “Subsequent Merger” and, together with the Merger and the other transactions contemplated by the Business Combination Agreement, the “Business Combination”); and (iii) JATT changed its name to “Zura Bio Limited” (the “Company” or “Zura Bio Limited”). In connection with JATT’s shareholder proposal to amend its amended and restated memorandum and articles of association to extend the date by which JATT was required to consummate a business combination, which was approved at an extraordinary general meeting held on January 12, 2023, the holders of 12,111,022 of JATT’s ordinary shares, par value $0.0001 per share (the “JATT Class A Ordinary Shares”), exercised their right to redeem their shares for cash at a redemption price of approximately $10.26 per share for an aggregate redemption amount of approximately $124,226,450.64. In connection with the Extraordinary General Meeting and the Business Combination, the holders of an additional 1,506,480 Ordinary Shares exercised their right to redeem their shares for cash at a redemption price of approximately $10.26 per share for an aggregate redemption amount of approximately $15,456,484.80. Prior to the Business Combination, holders of an aggregate of 13,617,502 Ordinary Shares exercised their right to redeem their shares for cash for an aggregate redemption amount of approximately $139,682,935.44. Conversion and Exchange of Equity in the Business Combination Pursuant to the Business Combination Agreement, all outstanding Holdco shares as of immediately prior to the Business Combination were cancelled in exchange for the right to receive a number of newly issued ordinary shares of JATT, par value $0.0001 per share (“Company Class A Ordinary Shares”), equal to the Exchange Ratio (as defined in the Business Combination Agreement) and all outstanding options to purchase shares of capital in Zura were exchanged for a number of options exercisable for newly issued Company Class A Ordinary Shares based upon the Exchange Ratio. The total consideration received by securityholders of Holdco at the Closing consisted of newly issued Company Class A Ordinary Shares (or options to purchase such shares) with an aggregate value equal to $165 million (the “Merger Consideration”). Subject to, and in accordance with, the terms and conditions of the Business Combination Agreement, in connection with the Merger and the Subsequent Merger, at the Closing, (i) each JATT unit was (to the extent not already separated) automatically separated and the holder thereof was deemed to hold one JATT Class A Ordinary Share and one-half of a JATT warrant; (ii) in consideration for the Merger, JATT issued to holders of Holdco’s issued and outstanding shares immediately prior to the Effective Time (as defined in the Business Combination Agreement) an aggregate of 14,558,067 JATT Class A Ordinary Shares (including 499,993 JATT Class A Ordinary Shares underlying restricted stock units granted to Amit Munshi, the Company’s Non-Executive Chairman) plus 1,941,933 options to acquire JATT Class A Ordinary Shares for which outstanding options to acquire Holdco ordinary shares were exchanged on Closing; and (iii) pursuant to the terms and conditions of JATT’s existing amended and restated memorandum and articles of association, all then-outstanding Class B ordinary shares, par value $0.0001 per share, were automatically converted into JATT Class A Ordinary Shares on a one-for-one basis. PIPE Subscription Agreements On the Closing Date, Ewon Comfortech Co., Ltd. (“Ewon”), an institutional accredited investor which is an indirect investor in Zura through its equity interest in Hana Immunotherapeutics LLC (“Hana”), purchased from JATT 2,000,000 JATT Class A Ordinary Shares and Eugene Investment & Securities Co., Ltd (“Eugene”), an unaffiliated institutional credited investor, purchased from JATT 9,950 JATT Class A Ordinary Shares (Ewon, together with Eugene, the “PIPE Investors”), for an aggregate of 2,009,950 JATT Class A Ordinary Shares (the “PIPE Shares”) at a price of $10.00 per share, for an aggregate purchase price of $20,099,500 (the “PIPE Financing”), pursuant to the subscription agreement entered into by JATT and the Ewon as of June 16, 2022, as amended on November 25, 2022 (the “Ewon PIPE Subscription Agreement”) and the subscription agreement entered into by JATT and Eugene as of March 13, 2023 (the “Eugene PIPE Subscription Agreement” and, together with the Ewon PIPE Subscription Agreement, the “PIPE Subscription Agreements”). Pursuant to the PIPE Subscription Agreements, JATT granted certain registration rights to the PIPE Investors with respect to the PIPE Shares. The sale of the PIPE Shares was consummated concurrently with the closing of the Business Combination. Forward Purchase Agreement At the Closing of the Business Combination, Athanor Master Fund, LP and Athanor International Master Fund, LP (collectively, the “FPA Investors”), each of which is an unaffiliated institutional investor, purchased (i) an aggregate of 3,000,000 JATT Class A Ordinary Shares at $10 per share for $30,000,000; (ii) an aggregate of 1,301,633 JATT Class A Ordinary Shares at $10 per share for $13,016,330 (the “Redemption Backstop”) as public share redemptions were greater than 90% at the time of the Business Combination (the “Excess Redemptions”); and (iii) an additional 2,500,000 JATT Class A Ordinary Shares in consideration for the FPA Investors entering into the latest amendment, but for no additional monetary consideration, pursuant to the forward purchase agreements JATT and the FPA Investors entered into on August 5, 2021, as amended and restated on January 27, 2022 and as amended on March 8, 2023 (the “Forward Purchase Agreement”). Sponsor Support Agreement Concurrently with the execution of the Business Combination Agreement, JATT, Zura, JATT Ventures, L.P., a Cayman Islands exempted limited partnership (the “Sponsor”) and certain directors and officers of JATT entered into a support agreement dated June 16, 2022 (the “Sponsor Support Agreement”), pursuant to which, among other things, the Sponsor and directors and officers of JATT agreed to (i) vote all of the JATT Class A Ordinary Shares beneficially owned by them, including any additional shares to which they acquire ownership of or the power to vote, in favor of the SPAC Shareholder Voting Matters (as defined in the Business Combination Agreement), (ii) not to redeem any of their JATT Class A Ordinary Shares in conjunction with shareholder approval of the Business Combination and (iii) be bound by certain transfer restrictions with respect to their JATT Class A Ordinary Shares. Company Shareholder Support Agreement Concurrently with the execution of the Business Combination Agreement, JATT, Zura and the shareholders of Zura entered into a support agreement dated June 16, 2022 (the “Company Shareholder Support Agreement”), pursuant to which the Zura shareholders agreed to vote all Zura ordinary shares beneficially owned by them, including any additional shares of Zura they acquire ownership of or the power to vote, in favor of the Business Combination and related transactions. Sponsor Forfeiture Agreement Contemporaneously with the execution of the Business Combination Agreement, the Sponsor entered into a sponsor forfeiture agreement (the “Sponsor Forfeiture Agreement”) with JATT and Zura, pursuant to which at the Closing, the Sponsor forfeited 4,133,466 of its private placement warrants to purchase JATT Class A Ordinary Shares, exercisable at $11.50 per share (the “Forfeited Private Placement Warrants”), acquired by the Sponsor in July 2021 upon JATT’s initial public offering, which were transferred to the FPA Investors and Ewon on a pro rata basis in accordance with the FPA Investors’ and Ewon’s total invested capital. The FPA Investors received an aggregate of 2,480,000 Forfeited Private Placement Warrants and Ewon received 1,653,466 Forfeited Private Placement Warrants. Lock-Up Agreement Contemporaneously with the execution of the Business Combination Agreement, JATT, the Sponsor, certain affiliates of the Sponsor and the Zura shareholders and optionholders, entered into a lock-up agreement (the “Lock-Up Agreement”), which took effect at Closing, containing restrictions on transfer with respect to Company Class A Ordinary Shares held by each such holder (subject to certain exceptions, the “Lock-Up Shares”) for a period as follows: one one one adjusted for share splits, share dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period on a VWAP (as defined below) basis during the relevant lock-up period; and (ii) the date on which JATT consummates a liquidation, merger, capital share exchange, reorganization, or other similar transaction that results in all of JATT’s shareholders having the right to exchange their JATT ordinary shares for cash, securities or other property. For purposes of the Lock-Up Agreement, “VWAP” means, for any date, the daily volume weighted average price of the JATT ordinary shares for such date (or the nearest preceding date) on the trading market on which the JATT ordinary shares are then listed or quoted as reported by Bloomberg L.P. (based on a trading day from 9:30 a.m. (New York City time) to 4:00 p.m. (New York City time)). Amendment to the Insider Letter Agreement In connection with the execution of the Business Combination Agreement, JATT, the Sponsor, members of JATT’s board of directors and certain other individuals (collectively, the “Insiders”) entered into an Amendment to the Insider Letter Agreement (the “Amended Insider Letter Agreement”), which provides, among other things, that certain of JATT’s Class B ordinary shares (the “Founder Shares”) (and any JATT Class A Ordinary Shares issuable upon conversion thereof) shall be subject to certain time and share-performance-based vesting provisions which are described below. The Sponsor and the Insiders agreed that they shall not transfer any Founder Shares until the earlier of (A) six months after the completion of the initial business combination and (B) the date following the completion of an initial business combination on which JATT completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of the public shareholders having the right to exchange their JATT Class A Ordinary Shares for cash, securities or other property. Notwithstanding the foregoing, if, subsequent to the Business Combination, the closing price of the JATT Class A Ordinary Shares equals or exceeds $12.00 per share (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30- trading day period commencing at least 150 days after the Business Combination, the Founder Shares shall be released from the lock-up restrictions. Lilly Lock-Up Agreement Pursuant to the Equity Grant Agreement (the “JATT Equity Grant Agreement”) entered into on December 8, 2023, by and between JATT and Eli Lilly and Company (“Lilly”), JATT and Lilly entered into a Lock-Up Agreement (the “Lilly Lock-Up Agreement”), on the Closing Date. The Lilly Lock-Up Agreement contains restrictions on transfer with respect to the shares issued to Lilly under the JATT Equity Grant Agreement (subject to certain exceptions, the “Lilly Lock-Up Shares”) for a period as follows: one one Amended and Restated Registration and Shareholders Rights Agreement In connection with the Closing, Zura, JATT and certain securityholders of each of Zura and JATT who received JATT Class A Ordinary Shares pursuant to the Business Combination Agreement, entered into an amended and restated registration and shareholders rights agreement (the “Registration Rights Agreement”), which became effective upon the consummation of the Business Combination. The Registration Rights Agreement governs the registration of certain of the Company Class A Ordinary Shares for resale and includes certain customary demand and “piggy-back” registration rights with respect to the Company Class A Ordinary Shares held by the parties thereto. Hydra Promissory Note On December 8, 2022, Zura and Hydra LLC, a Cayman Islands limited liability company managed and controlled by Verender S. Badial and Someit Sidhu (“Hydra”), entered into a promissory note (the “Hydra Promissory Note”) pursuant to which (i) Hydra loaned to Zura a principal amount (the “Principal Amount”) of $8 million (including an original issue discount of $400,000) with an interest rate equal to 9.0% per annum, compounding daily. Under the Hydra Promissory Note, Hydra had the right to accelerate the Hydra Promissory Note and receive an amount equal to 120% of the Principal Amount because the registration statement on Form S-4 relating to the Business Combination was not declared effective by the SEC on or before February 15, 2023. On March 8, 2023, Zura and Hydra signed a limited waiver letter under the Hydra Promissory Note (the “Waiver Letter”), pursuant to which Hydra agreed to waive its acceleration right in consideration of Zura paying to Hydra 125% of the Principal Amount (equal to $10,000,000 in the aggregate) on the earlier of December 8, 2023 and five As of the Closing Date and following the completion of the Business Combination, the Company had the following outstanding securities (including derivative securities): ● 27,552,148 Company Class A Ordinary Shares (including 499,993 Company Class A Ordinary Shares underlying restricted stock units (the “RSUs”)); ● 6,900,000 public warrants, each exercisable for one Company Class A Ordinary Share at a price of $11.50 per share (the “Public Warrants”); ● 5,910,000 private placement warrants, each exercisable for one Company Class A Ordinary Share at a price of $11.50 per share (the “Private Placement Warrants”); and ● 1,941,933 options, each exercisable for one Company Class A Ordinary Share (the “Options”). Liquidity and Capital Resources The Company’s liquidity needs through December 31, 2021, were satisfied through the cash contribution of $25,000 from the Sponsor to purchase Founder Shares (as defined in Note 4), and a loan from its Sponsor of approximately $117,000 under the Note (as defined in Note 4). The Company repaid the Note in full on July 21, 2021. Subsequent to the consummation of the Initial Public Offering, the Company’s liquidity has been satisfied through the net proceeds from the consummation of the Initial Public Offering and the Private Placement held outside of the Trust Account. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, provide the Company Working Capital Loans (as defined in Note 4). As of December 31, 2022 and 2021, there was approximately $356,000 and $0 outstanding under Working Capital Loans, respectively. |
SUMMARY OF SIGNIFICANT ACCOUNTI
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 12 Months Ended |
Dec. 31, 2022 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying consolidated financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC. Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Merger Sub and Merger Sub 2. All significant intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. There were no cash equivalents at December 31, 2022 and 2021. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal Depository Insurance Corporation coverage limit of $250,000, and any investments held in Trust Account. At December 31, 2022 and 2021, the Company had not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account. Investments Held in Trust Account The Company’s portfolio of investments is comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company’s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company’s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the consolidated balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in investment income on Trust Account in the accompanying consolidated statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information. Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities which qualify as financial instruments under the FASB ASC Topic 820, “Fair Value Measurements” (“ASC 820”), equal or approximate the carrying amounts represented in the consolidated balance sheets, primarily due to their short-term nature, or because the instrument is recognized at fair value. Fair Value Measurements Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers consist of: ● Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including funded loans and issued share purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and FASB ASC Topic 815, “Derivatives and Hedging” (“ASC 815”). The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. The warrants issued in connection with the Initial Public Offering (the “Public Warrants”) and the Private Placement Warrants are recognized as derivative liabilities in accordance with ASC 815. Accordingly, the Company recognizes the warrant instruments as liabilities at fair value and adjust the instruments to fair value at each reporting period. The liabilities are subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s consolidated statements of operations. The fair value of the Public Warrants and the Private Placement Warrants were initially measured at fair value using a Monte Carlo simulation and a Black Scholes option pricing model, respectively. The fair value of the Private Placement Warrants continues to be measured using a Black-Scholes option pricing model. The fair value of the Public Warrants are subsequently measured at their listed trading price since they began to be separately listed and traded beginning in September 2021. Derivative warrant liabilities are classified as non-current liabilities as their liquidation will not be reasonably expected to require the use of current assets or require the creation of current liabilities. Offering Costs Associated with Initial Public Offering Offering costs consisted of legal, accounting, underwriting fees and other costs incurred through the Initial Public Offering that were directly related to the Initial Public Offering. Offering costs are allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with derivative warrant liabilities were expensed as incurred and presented as non-operating expenses in the consolidated statements of operations. Offering costs associated with the Public Shares were charged to the carrying value of the Class A ordinary shares subject to possible redemption upon the completion of the Initial Public Offering. The Company classifies deferred underwriting commissions as non-current liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities. Class A Ordinary Shares Subject to Possible Redemption The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC 480. Class A ordinary shares subject to mandatory redemption (if any) is classified as liability instruments and are measured at fair value. Conditionally redeemable Class A ordinary shares (including Class A ordinary shares that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, Class A ordinary shares is classified as shareholders’ equity. The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. As of December 31, 2022 and 2021, 13,800,000 shares of Class A ordinary shares are subject to possible redemption and are presented at redemption value as temporary equity, outside of the shareholders’ equity section of the Company’s consolidated balance sheets. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of the Class A ordinary shares subject to possible redemption to equal the redemption value at the end of each reporting period. Effective with the closing of the Initial Public Offering (including the exercise of the over-allotment option), the Company recognized the fair value adjustment from initial book value to redemption amount, which resulted in charges against additional paid-in capital (to the extent available) and accumulated deficit. Income Taxes FASB ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2022 and 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman federal income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s consolidated financial statements. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. Net Income (Loss) Per Ordinary Share The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” The Company has two classes of shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Income and losses are shared pro rata between the two classes of shares. Net income (loss) per ordinary share is calculated by dividing the net income by the weighted average ordinary shares outstanding for the respective period. The calculation of diluted net income per share does not consider the effect of the warrants issued in connection with the Initial Public Offering (including exercise of the over-allotment option) and the Private Placement to purchase an aggregate of 12,810,000 ordinary shares because their exercise is contingent upon future events. The number of weighted average Class B ordinary shares for calculating basic net income per ordinary share was reduced for the effect of an aggregate of The following tables presents a reconciliation of the numerator and denominator used to compute basic and diluted net income (loss) per share for each class of ordinary shares. For The Year Ended December 31, 2022 Class A Class B Basic and diluted net income per ordinary share: Numerator: Allocation of net income - basic and diluted $ 2,839,302 $ 709,825 Denominator: Basic and diluted weighted average ordinary shares outstanding 13,800,000 3,450,000 Basic and diluted net income per ordinary share $ 0.21 $ 0.21 For The Period From March 10, 2021 (Inception) through December 31, 2021 Class A Class B Basic and diluted net income per ordinary share: Numerator: Allocation of net income (loss) - basic $ 4,893,422 $ 1,955,233 Allocation of net income (loss) - diluted 4,814,256 2,034,389 Denominator: Basic and diluted weighted average ordinary shares outstanding 7,834,343 3,130,303 Diluted weighted average ordinary shares outstanding 7,834,343 3,310,606 Basic net income per ordinary share $ 0.62 $ 0.62 Diluted net income per ordinary share $ 0.61 $ 0.61 Recent Accounting Pronouncements In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. The Company adopted ASU 2020-06 on March 10, 2021 (inception). Adoption of the ASU did not impact the Company’s financial position, results of operations or cash flows. Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s consolidated financial statements. |
INITIAL PUBLIC OFFERING
INITIAL PUBLIC OFFERING | 12 Months Ended |
Dec. 31, 2022 | |
INITIAL PUBLIC OFFERING | |
INITIAL PUBLIC OFFERING | NOTE 3. INITIAL PUBLIC OFFERING On July 16, 2021, the Company consummated its Initial Public Offering of 12,000,000 Units, at $10.00 per Unit, generating gross proceeds of $120.0 million, and incurring offering costs of approximately $10.5 million (net of reimbursement from the underwriters of $480,000), of which approximately $3.4 million was for deferred underwriting commissions, approximately $4.7 million was incentives provided to Anchor Investors by the Sponsor (see Note 4), and approximately $685,000 was allocated to offering costs associated with derivative warrant liabilities. On July 19, 2021, the underwriters fully exercised their option and purchased 1,800,000 additional Units, generating gross proceeds of $18.0 million, and incurring offering costs of $990,000, of which $630,000 was for deferred underwriting commissions and approximately $62,000 was allocated to offering costs associated with the derivative warrant liabilities. Each Unit consists of one Class A ordinary share and one |
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS | 12 Months Ended |
Dec. 31, 2022 | |
RELATED PARTY TRANSACTIONS | |
RELATED PARTY TRANSACTIONS | NOTE 4. RELATED PARTY TRANSACTIONS Founder Shares On March 22, 2021, the Sponsor purchased 4,312,500 founder shares (“Founder Shares”), which are Class B ordinary shares, for an aggregate purchase price of $25,000, or approximately $0.006 per share. On June 14, 2021, Sponsor effected a surrender of 862,500 Class B ordinary shares to us for no consideration, resulting in a decrease in the total number of Class B ordinary shares outstanding from 4,312,500 to 3,450,000. All shares and share amounts have been retroactively adjusted. The holders of the Founder Shares agreed to surrender and cancel up to an aggregate of 450,000 Founder Shares, on a pro rata basis, to the extent that the option to purchase additional Units was not exercised in full by the underwriters, so that the Founder Shares would represent approximately 20% of the Company’s issued and outstanding shares after the Initial Public Offering. The underwriters fully exercised their over-allotment option on July 19, 2021; therefore, these 450,000 Founder Shares were no longer subject to possible redemption. In connection with the closing of the IPO and sale of Units to the Anchor Investors, in exchange for the Anchor Investors’ participation in the Initial Public Offering, the Sponsor sold and transferred membership interests in the Sponsor that, in aggregate, represent an indirect economic interest in 917,365 Founder Shares and 2,490,500 Private Placement Warrants. The Anchor Investors paid approximately $2.5 million in total for the Sponsor membership interests, resulting in each Anchor Investor effectively paying $1.00 per Private Placement Warrant and approximately $0.008 per Founder Share. The Company determined that the aggregate fair value of the Sponsor membership interests sold to the Anchor Investors was approximately $7.2 million. To estimate the fair value of Sponsor membership interests, management considered the probability and timing of IPO completion, business combination completion, and an appropriate discount for lack of marketability, all Level 3 inputs under ASC 820. The excess of the fair value of the Sponsor membership interests issued to the Anchor Investors over the aggregate consideration paid for such interests was considered to be an offering cost of the Company’s Initial Public Offering, in accordance with Staff Accounting Bulletin Topic 5A, and a deemed divided to the Company from the Sponsor for the same amount. The Initial Shareholders agreed not to transfer, assign or sell any of their Founder Shares until the earlier to occur of: (A) one year after the completion of the initial Business Combination and (B) subsequent to the initial Business Combination, (x) if the closing price of Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, share exchange or other similar transaction that results in all of the Public Shareholders having the right to exchange their ordinary shares for cash, securities or other property. Private Placement Simultaneously with the closing of the Initial Public Offering, the Company consummated the Private Placement of 5,370,000 Private Placement Warrants, at a price of $1.00 per Private Placement Warrant to the Sponsor, and Anchor Investors, generating proceeds of approximately $5.4 million. Concurrent with the consummation of the Over-Allotment on July 19, 2021, the Sponsor purchased 540,000 additional Private Placement Warrants, generating proceeds of $540,000. The Anchor Investors purchased an indirect economic interest in 2,490,500 of the warrants in the Private Placement and the Second Private Placement. Each whole Private Placement Warrant is exercisable for one whole share of Class A ordinary shares at a price of $11.50 per share. A portion of the proceeds from the sale of the Private Placement Warrants was added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the Private Placement Warrants will expire worthless. The Private Placement Warrants will be non-redeemable for cash and exercisable on a cashless basis so long as they are held by the Sponsor or their permitted transferees. The Sponsor, Anchor Investors and the Company’s officers and directors agreed, subject to limited exceptions, not to transfer, assign or sell any of their Private Placement Warrants until 30 days after the completion of the initial Business Combination. Related Party Loans On March 22, 2021, the Sponsor agreed to loan the Company up to $200,000 pursuant to a promissory note (the “Note”). The Note was non-interest bearing, unsecured and due on the closing date of the Initial Public Offering. As of June 30, 2021, the Company borrowed approximately $117,000 under the Note. The Company repaid the Note in full on July 21, 2021. As of December 31, 2022 and 2021, there was no balance outstanding. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor, members of the Company’s founding team or any of their affiliates may, but are not obligated to, loan the Company funds as may be required. If the Company completes a Business Combination, the Company would repay the loans out of the proceeds of the Trust Account released to the Company. Otherwise, the loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the loans but no proceeds held in the Trust Account would be used to repay the loans. The loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1.5 million of such loans may be convertible into warrants of the post Business Combination entity at a price of $1.00 per warrant. The warrants will be identical to the Private Placement Warrants. On May 11, 2022, an affiliate of the Sponsor agreed to loan the Company up to $300,000 to cover ongoing expenses of the Company pursuant to a promissory note (the “Working Capital Loan”). The Working Capital Loan does not bear interest and will mature upon closing of an initial Business Combination. In the event that a Business Combination does not close prior to April 17, 2023, the Working Capital Loan shall be deemed to be terminated and no amounts will thereafter be due under the Working Capital Loan. The principal balance may not be prepaid without the consent of the lender. The Working Capital Loan is convertible, at the lender’s discretion, into warrants of the Company at a price of $1.00 per warrant. The warrants would be identical to the Private Placement Warrants. The Working Capital Loan contains customary events of default, including, among others, those relating to the Company’s failure to make a payment of principal when due and to perform any other obligations that is not timely cured after written notice of such default from the sponsor. On November 2, 2022, an affiliate of the Sponsor agreed to loan the Company up to $500,000 to cover ongoing expenses of the Company pursuant to a promissory note. The promissory note does not bear interest and will mature upon closing of an initial Business Combination. In the event that a Business Combination does not close prior to April 17, 2023, the promissory note shall be deemed to be terminated and no amounts will thereafter be due under the promissory note. The principal balance may not be prepaid without the consent of the lender. The promissory note is convertible, at the lender’s discretion, into warrants of the Company at a price of $1.00 per warrant. The warrants would be identical to the Private Placement Warrants. The promissory note contains customary events of default, including, among others, those relating to the Company’s failure to make a payment of principal when due and to perform any other obligations that is not timely cured after written notice of such default from the sponsor. To-date, no amounts have been borrowed by the Company under the promissory note. As of December 31, 2022 and 2021, there was approximately $356,000 and $0 outstanding under Working Capital Loans, respectively. The conversion option is an embedded derivative under ASC 815 that is required to be separately measured at fair value with subsequent changes in fair value recognized in Company’s consolidated statements of operations each reporting period until the Working Capital Loan is repaid, converted or terminated. The embedded conversion option was determined to have de minimis value as of each funding date and at December 31, 2022. The Company valued the embedded conversion option using a Black-Scholes option model assuming the warrants as the underlying. The traded price of the Public Warrants as of each funding date and on December 31, 2022 was used as a proxy for the underlying warrant price. The time to maturity was estimated based on management’s estimated time to close a Business Combination. The volatility was derived from the traded prices of the Public Warrants. Support Agreement and Services The Company agreed to pay the Sponsor a total of $10,000 per month, commencing on the date of listing on the NYSE, for office space, utilities, secretarial and administrative support services provided to members of the management team. Upon completion of the initial Business Combination or the Company’s liquidation, the Company will cease paying these monthly fees. For the year ended December 31, 2022 and for the period from March 10, 2021 (inception) through December 31, 2021, the Company incurred such fees of $120,000 and $55,000, respectively, included as general and administrative fees – related party on the consolidated statements of operations. As of December 31, 2022 and 2021, approximately $78,000 and $18,000, respectively, has been included for such services and is included as due from related party on the accompanying consolidated balance sheets. An affiliate of the Company’s Sponsor and CFO provides office space and consulting services to the Company. For the year ended December 31, 2022 and for the period from March 10, 2021 (inception) through December 31, 2021, the Company incurred fees of $60,000 and $113,000,respectively, included as general and administrative fees – related party on the consolidated statements of operations. As of December 31, 2022 and 2021, there is no balance owed for these services. For the year ended December 31, 2022 and for the period from March 10, 2021 (inception) through December 31, 2021, the Company incurred merger consulting fees of $201,000 and $0, respectively, included as general and administrative fees - related party on the consolidated statements of operations. Forward Purchase Agreements On August 5, 2021, the Company entered into Forward Purchase Agreements with certain Anchor Investors, Athanor Master Fund LP (“AMF”) and with Athanor International Master Fund, LP (“AIF”) (collectively the “Forward Purchase Agreements”, and collectively, “AMF and AIF are “Purchasers”). Pursuant to the Forward Purchase Agreements, the Company shall issue and sell to the Purchasers, and the Purchasers shall purchase from the Company, an aggregate of 7,500,000 forward purchase shares, or “Forward Purchase Shares”, for a purchase price of $10.00 per Forward Purchase Share, or $75,000,000 in the aggregate. Each Forward Purchase Share will consist of one Class A ordinary share of the Company. The Class A ordinary shares will have the same terms as the Company’s publicly traded Class A ordinary shares but will be restricted securities and not be freely tradable until registered with the SEC. In January 2022, the Forward Purchase Agreements were amended (“Amended Forward Purchase Agreements”) to: i) reduce the number of forward purchase shares from an aggregate of 7,500,000 to 3,000,000 and from a total $75,000,000 in the aggregate to $30,000,000 in the aggregate; and ii) to add a requirement for the Purchasers to provide a binding redemption backstop (the “Redemption Backstop”) to purchase an additional $15 million of the redeeming shares in the event that redemptions are greater than 90% in connection with a Business Combination (the “Excess Redemptions”); and iii) to add a requirement that at the time of entering into a binding agreement for the Business Combination, the Purchasers will directly provide the target merger company (Target”) with bridge financing of $30 million evidenced by a convertible promissory note (“Convertible Note”) which shall be convertible into the Company’s Class A ordinary shares at the closing of the Business Combination. |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 12 Months Ended |
Dec. 31, 2022 | |
COMMITMENTS AND CONTINGENCIES. | |
COMMITMENTS AND CONTINGENCIES | NOTE 5. COMMITMENTS AND CONTINGENCIES Registration and Shareholder Rights The holders of the Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans) are entitled to registration rights pursuant to a registration and shareholder rights agreement. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of the initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. Underwriting Agreement The Company granted the underwriter a 45-day option from the date of the Initial Public Offering to purchase up to 1,800,000 additional Units at the Initial Public Offering price less the underwriting discounts and commissions. The underwriter fully exercised its over-allotment option on July 19, 2021. The underwriter was paid an underwriting discount of $0.20 per unit, or approximately $2.4 million in the aggregate upon the closing of the Initial Public Offering. In addition, the Company received a reimbursement from the underwriter of $480,000 to cover for certain offering expenses. In addition, $0.35 per unit, or approximately $3.4 million in the aggregate (net of the reimbursement from the underwriter of $820,000 from the deferred commissions for business combination expenses) will be payable to the underwriter for deferred underwriting commissions. The deferred fee will become payable to the underwriter from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. In connection with the consummation of the Over-Allotment on July 19, 2021, the underwriter was paid an additional fee of $360,000 and an additional amount of $630,000 is payable as deferred underwriting commissions. Risks and Uncertainties Management continues to evaluate the impact of the COVID-19 pandemic and has concluded that, while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations, close of the Initial Public Offering and/or search for a target company, the specific impact is not readily determinable as of the date of these consolidated financial statements. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. In February 2022, the Russian Federation and Belarus commenced a military action with the country of Ukraine. As a result of this action, various nations, including the United States, have instituted economic sanctions against the Russian Federation and Belarus. Further, the impact of this action and related sanctions on the world economy are not determinable as of the date of these consolidated financial statements. The specific impact on the Company’s financial condition, results of operations, and cash flows is also not determinable as of the date of these consolidated financial statements. |
CLASS A ORDINARY SHARES SUBJECT
CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION | 12 Months Ended |
Dec. 31, 2022 | |
CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION | |
CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION | NOTE 6. CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of future events. The Company is authorized to issue 200,000,000 shares of Class A ordinary shares with a par value of $ 0.0001 per share. Holders of the Company’s Class A ordinary shares are entitled to one vote for each share. As of December 31, 2022 and 2021, there were 13,800,000 shares of Class A ordinary shares issued and outstanding , all of which were subject to possible redemption and are classified outside of permanent equity in the consolidated balance sheets. Class A ordinary shares subject to possible redemption reflected on the consolidated balance sheets is reconciled on the following table: Gross proceeds $ 138,000,000 Less: Proceeds allocated to Public Warrants (8,625,000) Class A ordinary share issuance costs, net of reimbursement from underwriter (9,150,115) Plus: Accretion of carrying value to redemption value 19,155,115 Class A common stock subject to possible redemption - December 31, 2021 139,380,000 Increase in redemption value of Class A common stock subject to possible redemption 1,994,352 Class A common stock subject to possible redemption - December 31, 2022 $ 141,374,352 |
SHAREHOLDERS' DEFICIT
SHAREHOLDERS' DEFICIT | 12 Months Ended |
Dec. 31, 2022 | |
SHAREHOLDERS' DEFICIT | |
SHAREHOLDERS' DEFICIT | NOTE 7. SHAREHOLDERS’ DEFICIT Preference Shares — outstanding Class A Ordinary Shares — Class B Ordinary Shares — outstanding Ordinary shareholders of record are entitled to one vote for each share held on all matters to be voted on by shareholders. Holders of Class A ordinary shares and holders of Class B ordinary shares will vote together as a single class on all matters submitted to a vote of the shareholders except as required by law. The Class B ordinary shares will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the initial Business Combination on a one-for-one basis, subject to adjustment for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like, and subject to further adjustment as provided herein. In the case that additional Class A ordinary shares or equity-linked securities are issued or deemed issued in connection with the initial Business Combination, the number of Class A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate, 20% of the total number of ordinary shares outstanding after such conversion, including the total number of Class A ordinary shares issued, or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial Business Combination, excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, or to be issued, to any seller in the initial Business Combination, any private placement warrants issued to the Sponsor, officers or directors upon conversion of Working Capital Loans; provided that such conversion of Founder Shares will never occur on a less than one-for-one basis. |
DERIVATIVE WARRANT LIABILITIES
DERIVATIVE WARRANT LIABILITIES | 12 Months Ended |
Dec. 31, 2022 | |
DERIVATIVE WARRANT LIABILITIES | |
DERIVATIVE WARRANT LIABILITIES | NOTE 8. DERIVATIVE WARRANT LIABILITIES As of December 31, 2022 and 2021, the Company had an aggregate of 12,810,000 warrants outstanding, comprised of 6,900,000 and 5,910,000 Public Warrants and Private Placement Warrants, respectively. The Company accounts for the warrants as derivative warrant liabilities in accordance with the guidance contained in ASC 815. Such guidance provides that because the warrants do not meet the criteria for equity treatment thereunder, each warrant must be recorded as a liability due to the existence of provisions whereby adjustments to the exercise price of the warrants is based on a variable that is not an input to the fair value of a “fixed-for-fixed” option and the existence of the potential for net cash settlement for the warrant holders (but not all shareholders) in the event of a tender offer. Public Warrants may only be exercised for a whole number of shares. No fractional Public Warrants will be issued upon separation of the Units and only whole Public Warrants will trade. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of a Business Combination and (b) 12 months from the closing of the Proposed Public Offering; provided in each case that the Company has an effective registration statement under the Securities Act covering the Class A ordinary shares issuable upon exercise of the Public Warrants and a current prospectus relating to them is available and such shares are registered, qualified or exempt from registration under the securities laws of the state of residence of the holder (or the Company permit holders to exercise their warrants on a cashless basis under certain circumstances). The Company has agreed that as soon as practicable, but in no event later than 45 business days after the closing of the initial Business Combination, the Company will use commercially reasonable efforts to file with the SEC and have an effective registration statement covering the Class A ordinary shares issuable upon exercise of the warrants and to maintain a current prospectus relating to those Class A ordinary shares until the warrants expire or are redeemed, as specified in the warrant agreement. If a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants is not effective by the 60th The warrants have an exercise price of $11.50 per share, subject to adjustments, and will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation. In addition, if (x) the Company issues additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per Class A ordinary share (with such issue price or effective issue price to be determined in good faith by the board of directors and, in the case of any such issuance to the initial shareholders or their affiliates, without taking into account any Founder Shares held by the initial shareholders or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Class A ordinary shares during the 10 trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market Value”) is below $9.20 per share, then the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger prices described under “Redemption of warrants when the price per Class A ordinary share equals or exceeds $18.00” and “Redemption of warrants when the price per Class A ordinary share equals or exceeds $10.00” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, and the $10.00 per share redemption trigger price described under “Redemption of warrants when the price per Class A ordinary share equals or exceeds $10.00” will be adjusted (to the nearest cent) to be equal to the higher of the Market Value and the Newly Issued Price. The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Proposed Public Offering, except that the Private Placement Warrants and the Class A ordinary shares issuable upon exercise of the Private Placement Warrants will not be transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants will be non-redeemable so long as they are held by the initial purchasers or such purchasers’ permitted transferees. If the Private Placement Warrants are held by someone other than the Initial Shareholders or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants. Redemption of warrants when the price per Class A ordinary share equals or exceeds $18.00 : ● in whole and not in part; ● at a price of $0.01 per warrant; ● upon a minimum of 30 days ’ prior written notice of redemption to each warrant holder; and ● if, and only if, the last reported sale price (the “closing price”) of Class A ordinary shares equals or exceeds $18.00 per share (as adjusted) for any 20 trading days within a 30 -trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders. The Company will not redeem the warrants as described above unless a registration statement under the Securities Act covering the Class A ordinary shares issuable upon exercise of the warrants is then effective and a current prospectus relating to those Class A ordinary shares is available throughout the 30-day redemption period. In no event will the Company be required to net cash settle any warrant. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless. |
FAIR VALUE MEASUREMENTS
FAIR VALUE MEASUREMENTS | 12 Months Ended |
Dec. 31, 2022 | |
FAIR VALUE MEASUREMENTS | |
FAIR VALUE MEASUREMENTS | NOTE 9 — FAIR VALUE MEASUREMENTS The following tables presents information about the Company’s financial assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2022 and 2021, by level within the fair value hierarchy: December 31, 2022 Quoted Prices in Active Significant Other Significant Other Markets Observable Inputs Unobservable Inputs Description (Level 1) (Level 2) (Level 3) Assets: Investments held in Trust Account - U.S. Treasury Securities $ 141,474,352 $ — $ — Liabilities: Derivative warrant liabilities - Public Warrants $ 1,035,000 $ — $ — Derivative warrant liabilities - Private Warrants $ — $ — $ 886,500 December 31, 2021 Quoted Prices in Active Significant Other Significant Other Markets Observable Inputs Unobservable Inputs Description (Level 1) (Level 2) (Level 3) Assets: Investments held in Trust Account - U.S. Treasury Securities $ 139,399,054 $ — $ — Liabilities: Derivative warrant liabilities - Public Warrants $ 3,174,000 $ — $ — Derivative warrant liabilities - Private Warrants $ — $ — $ 2,895,900 Transfers to/from Levels 1, 2, and 3 are recognized at the beginning of the reporting period. The estimated fair value of the Public Warrants transferred from a Level 3 fair value measurement to a Level 1 fair value measurement, when the Public Warrants were separately listed and traded in September 2021. Level 1 instruments include investments in U.S Treasury securities or money market funds that invest in U.S. Treasury securities. The Company uses inputs such as actual trade data, benchmark yields, quoted market prices from dealers or brokers, and other similar sources to determine the fair value of its investments. The fair value of the Public Warrants as of December 31, 2022 and 2021, was measured utilizing the Level 1 input of the observable listed trading price for such warrants. The fair value of the Public Warrants and the Private Placement Warrants were initially measured at fair value using a Monte Carlo simulation and a Black Scholes option pricing model, respectively. The fair value of the Private Placement Warrants continues to be measured using a Black-Scholes option pricing model. Inherent in a Monte Carlo simulation and a Black Scholes option pricing model are assumptions related to expected stock-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its warrants based on implied volatility from the Company’s traded warrants and from historical volatility of select peer company’s ordinary shares that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero. The following table provides quantitative information regarding Level 3 fair value measurements inputs used to estimate fair value of the warrants at their measurement dates: As of December 31, 2022 As of December 31, 2021 Exercise price $ 11.50 $ 11.50 Stock price $ 10.21 $ 9.87 Volatility 1.0 % 9.5 % Term (years) 4.46 0.54 Risk-free rate 4.05 % 1.43 % Dividend yield 0.0 % 0.0 % The change in the fair value of warrants measured with Level 3 inputs for the year ended December 31, 2022 and for the period from March 10, 2021 (inception) through December 31, 2021, is summarized as follows: Derivative warrant liabilities at December 31, 2021 - Level 3 $ 2,895,900 Change in fair value of derivative warrant liabilities (2,009,400) Derivative warrant liabilities at December 31, 2022 - Level 3 $ 886,500 Derivative warrant liabilities at March 10, 2021 $ — Issuance of Public and Private Warrants - Level 3 - July 2021 16,308,000 Transfer of Public Warrants to Level 1 measurement (8,625,000) Change in fair value of derivative warrant liabilities (4,787,100) Derivative warrant liabilities at December 31, 2021 - Level 3 $ 2,895,900 |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 12 Months Ended |
Dec. 31, 2022 | |
SUBSEQUENT EVENTS | |
SUBSEQUENT EVENTS | NOTE 10. SUBSEQUENT EVENTS The Company evaluated subsequent events and transactions that occurred up to the date the consolidated financial statements were issued and disclosed the closing of the Business Combination on March 20, 2023, as per Note 1. The Company did not identify any subsequent events that would have required adjustment or disclosure in the consolidated financial statements. |
SUMMARY OF SIGNIFICANT ACCOUN_2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 12 Months Ended |
Dec. 31, 2022 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | |
Basis of Presentation | Basis of Presentation The accompanying consolidated financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC. |
Emerging Growth Company | Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. |
Principles of Consolidation | Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Merger Sub and Merger Sub 2. All significant intercompany accounts and transactions have been eliminated in consolidation. |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. |
Cash and Cash Equivalents | Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. There were no cash equivalents at December 31, 2022 and 2021. |
Concentration of Credit Risk | Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal Depository Insurance Corporation coverage limit of $250,000, and any investments held in Trust Account. At December 31, 2022 and 2021, the Company had not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account. |
Investments Held in Trust Account | Investments Held in Trust Account The Company’s portfolio of investments is comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company’s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company’s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the consolidated balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in investment income on Trust Account in the accompanying consolidated statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information. |
Fair Value of Financial Instruments | Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities which qualify as financial instruments under the FASB ASC Topic 820, “Fair Value Measurements” (“ASC 820”), equal or approximate the carrying amounts represented in the consolidated balance sheets, primarily due to their short-term nature, or because the instrument is recognized at fair value. |
Fair Value Measurements | Fair Value Measurements Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers consist of: ● Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. |
Derivative Financial Instruments | Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including funded loans and issued share purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and FASB ASC Topic 815, “Derivatives and Hedging” (“ASC 815”). The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. The warrants issued in connection with the Initial Public Offering (the “Public Warrants”) and the Private Placement Warrants are recognized as derivative liabilities in accordance with ASC 815. Accordingly, the Company recognizes the warrant instruments as liabilities at fair value and adjust the instruments to fair value at each reporting period. The liabilities are subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s consolidated statements of operations. The fair value of the Public Warrants and the Private Placement Warrants were initially measured at fair value using a Monte Carlo simulation and a Black Scholes option pricing model, respectively. The fair value of the Private Placement Warrants continues to be measured using a Black-Scholes option pricing model. The fair value of the Public Warrants are subsequently measured at their listed trading price since they began to be separately listed and traded beginning in September 2021. Derivative warrant liabilities are classified as non-current liabilities as their liquidation will not be reasonably expected to require the use of current assets or require the creation of current liabilities. |
Offering Costs Associated with Initial Public Offering | Offering Costs Associated with Initial Public Offering Offering costs consisted of legal, accounting, underwriting fees and other costs incurred through the Initial Public Offering that were directly related to the Initial Public Offering. Offering costs are allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with derivative warrant liabilities were expensed as incurred and presented as non-operating expenses in the consolidated statements of operations. Offering costs associated with the Public Shares were charged to the carrying value of the Class A ordinary shares subject to possible redemption upon the completion of the Initial Public Offering. The Company classifies deferred underwriting commissions as non-current liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities. |
Class A Ordinary Shares Subject to Possible Redemption | Class A Ordinary Shares Subject to Possible Redemption The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC 480. Class A ordinary shares subject to mandatory redemption (if any) is classified as liability instruments and are measured at fair value. Conditionally redeemable Class A ordinary shares (including Class A ordinary shares that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, Class A ordinary shares is classified as shareholders’ equity. The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. As of December 31, 2022 and 2021, 13,800,000 shares of Class A ordinary shares are subject to possible redemption and are presented at redemption value as temporary equity, outside of the shareholders’ equity section of the Company’s consolidated balance sheets. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of the Class A ordinary shares subject to possible redemption to equal the redemption value at the end of each reporting period. Effective with the closing of the Initial Public Offering (including the exercise of the over-allotment option), the Company recognized the fair value adjustment from initial book value to redemption amount, which resulted in charges against additional paid-in capital (to the extent available) and accumulated deficit. |
Income Taxes | Income Taxes FASB ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2022 and 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman federal income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s consolidated financial statements. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. |
Net Income (Loss) Per Ordinary Share | Net Income (Loss) Per Ordinary Share The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” The Company has two classes of shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Income and losses are shared pro rata between the two classes of shares. Net income (loss) per ordinary share is calculated by dividing the net income by the weighted average ordinary shares outstanding for the respective period. The calculation of diluted net income per share does not consider the effect of the warrants issued in connection with the Initial Public Offering (including exercise of the over-allotment option) and the Private Placement to purchase an aggregate of 12,810,000 ordinary shares because their exercise is contingent upon future events. The number of weighted average Class B ordinary shares for calculating basic net income per ordinary share was reduced for the effect of an aggregate of The following tables presents a reconciliation of the numerator and denominator used to compute basic and diluted net income (loss) per share for each class of ordinary shares. For The Year Ended December 31, 2022 Class A Class B Basic and diluted net income per ordinary share: Numerator: Allocation of net income - basic and diluted $ 2,839,302 $ 709,825 Denominator: Basic and diluted weighted average ordinary shares outstanding 13,800,000 3,450,000 Basic and diluted net income per ordinary share $ 0.21 $ 0.21 For The Period From March 10, 2021 (Inception) through December 31, 2021 Class A Class B Basic and diluted net income per ordinary share: Numerator: Allocation of net income (loss) - basic $ 4,893,422 $ 1,955,233 Allocation of net income (loss) - diluted 4,814,256 2,034,389 Denominator: Basic and diluted weighted average ordinary shares outstanding 7,834,343 3,130,303 Diluted weighted average ordinary shares outstanding 7,834,343 3,310,606 Basic net income per ordinary share $ 0.62 $ 0.62 Diluted net income per ordinary share $ 0.61 $ 0.61 |
Recent Accounting Pronouncements | Recent Accounting Pronouncements In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. The Company adopted ASU 2020-06 on March 10, 2021 (inception). Adoption of the ASU did not impact the Company’s financial position, results of operations or cash flows. Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s consolidated financial statements. |
SUMMARY OF SIGNIFICANT ACCOUN_3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | |
Schedule of earnings per share basic and diluted | For The Year Ended December 31, 2022 Class A Class B Basic and diluted net income per ordinary share: Numerator: Allocation of net income - basic and diluted $ 2,839,302 $ 709,825 Denominator: Basic and diluted weighted average ordinary shares outstanding 13,800,000 3,450,000 Basic and diluted net income per ordinary share $ 0.21 $ 0.21 For The Period From March 10, 2021 (Inception) through December 31, 2021 Class A Class B Basic and diluted net income per ordinary share: Numerator: Allocation of net income (loss) - basic $ 4,893,422 $ 1,955,233 Allocation of net income (loss) - diluted 4,814,256 2,034,389 Denominator: Basic and diluted weighted average ordinary shares outstanding 7,834,343 3,130,303 Diluted weighted average ordinary shares outstanding 7,834,343 3,310,606 Basic net income per ordinary share $ 0.62 $ 0.62 Diluted net income per ordinary share $ 0.61 $ 0.61 |
CLASS A ORDINARY SHARES SUBJE_2
CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION | |
Summary of reconciliation of Class A common stock reflected on the balance sheet | Gross proceeds $ 138,000,000 Less: Proceeds allocated to Public Warrants (8,625,000) Class A ordinary share issuance costs, net of reimbursement from underwriter (9,150,115) Plus: Accretion of carrying value to redemption value 19,155,115 Class A common stock subject to possible redemption - December 31, 2021 139,380,000 Increase in redemption value of Class A common stock subject to possible redemption 1,994,352 Class A common stock subject to possible redemption - December 31, 2022 $ 141,374,352 |
FAIR VALUE MEASUREMENTS (Tables
FAIR VALUE MEASUREMENTS (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
FAIR VALUE MEASUREMENTS | |
Schedule of company's financial assets and liabilities that are measured at fair value on a recurring basis | December 31, 2022 Quoted Prices in Active Significant Other Significant Other Markets Observable Inputs Unobservable Inputs Description (Level 1) (Level 2) (Level 3) Assets: Investments held in Trust Account - U.S. Treasury Securities $ 141,474,352 $ — $ — Liabilities: Derivative warrant liabilities - Public Warrants $ 1,035,000 $ — $ — Derivative warrant liabilities - Private Warrants $ — $ — $ 886,500 December 31, 2021 Quoted Prices in Active Significant Other Significant Other Markets Observable Inputs Unobservable Inputs Description (Level 1) (Level 2) (Level 3) Assets: Investments held in Trust Account - U.S. Treasury Securities $ 139,399,054 $ — $ — Liabilities: Derivative warrant liabilities - Public Warrants $ 3,174,000 $ — $ — Derivative warrant liabilities - Private Warrants $ — $ — $ 2,895,900 |
Schedule of quantitative information regarding Level 3 fair value measurements inputs | As of December 31, 2022 As of December 31, 2021 Exercise price $ 11.50 $ 11.50 Stock price $ 10.21 $ 9.87 Volatility 1.0 % 9.5 % Term (years) 4.46 0.54 Risk-free rate 4.05 % 1.43 % Dividend yield 0.0 % 0.0 % |
Schedule of change in the fair value of warrants measured with Level 3 inputs | Derivative warrant liabilities at December 31, 2021 - Level 3 $ 2,895,900 Change in fair value of derivative warrant liabilities (2,009,400) Derivative warrant liabilities at December 31, 2022 - Level 3 $ 886,500 Derivative warrant liabilities at March 10, 2021 $ — Issuance of Public and Private Warrants - Level 3 - July 2021 16,308,000 Transfer of Public Warrants to Level 1 measurement (8,625,000) Change in fair value of derivative warrant liabilities (4,787,100) Derivative warrant liabilities at December 31, 2021 - Level 3 $ 2,895,900 |
DESCRIPTION OF ORGANIZATION, _2
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION (Details) | 10 Months Ended | 12 Months Ended | |||
Jul. 19, 2021 USD ($) shares | Jul. 16, 2021 USD ($) $ / shares shares | Mar. 10, 2021 item | Dec. 31, 2021 USD ($) | Dec. 31, 2022 USD ($) $ / shares | |
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | |||||
Condition for future business combination number of businesses minimum | item | 1 | ||||
Investment of cash into trust account | $ 139,400,000 | $ 139,380,000 | |||
Per unit amount of investment in trust account | $ / shares | $ 10.10 | $ 10.10 | |||
Minimum net tangible assets upon consummation of the business combination | $ 5,000,001 | ||||
Redemption limit percentage without prior consent | 15 | ||||
Obligation to redeem public shares if entity does not complete a business combination (as a percent) | 100% | ||||
Redemption period upon closure | 10 days | ||||
Maximum allowed dissolution expenses | $ 100,000 | ||||
Minimum | |||||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | |||||
Acquires assets as a percentage of net market value of assets held in trust account | 80% | ||||
Condition for future business combination threshold Percentage Ownership | 50 | ||||
IPO | |||||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | |||||
Number of units sold | shares | 1,800,000 | 12,000,000 | |||
Price per share | $ / shares | $ 10 | ||||
Proceeds received from initial public offering gross | $ 18,000,000 | $ 120,000,000 | |||
Offering costs, net of reimbursement from underwriter | 10,500,000 | ||||
Offering costs reimbursement from underwriter | 480,000 | ||||
Deferred underwriting commissions | $ 3,400,000 | ||||
Offering costs allocated to derivate warrant liabilities | $ 62,000 | ||||
Maximum allowed dissolution expenses | $ 100,000 | ||||
Private Placement | Private Placement | |||||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | |||||
Sale of private placement warrants (in shares) | shares | 5,370,000 | ||||
Price of warrant | $ / shares | $ 1 | ||||
Proceeds from sale of private placement warrants | $ 5,400,000 | ||||
Over-Allotment option | |||||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | |||||
Number of units sold | shares | 1,800,000 | ||||
Proceeds received from initial public offering gross | $ 18,000,000 | ||||
Deferred underwriting commissions | 630,000 | ||||
Offering costs | 990,000 | ||||
Offering costs allocated to derivate warrant liabilities | $ 62,000 | ||||
Sponsor | IPO | |||||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | |||||
Offering costs | 4,700,000 | ||||
Offering costs allocated to derivate warrant liabilities | $ 685,000 | ||||
Sponsor | Private Placement | |||||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | |||||
Sale of private placement warrants (in shares) | shares | 540,000 | 5,370,000 | |||
Price of warrant | $ / shares | $ 1 | ||||
Proceeds from sale of private placement warrants | $ 540,000 | $ 5,400,000 | |||
Sponsor | Private Placement | Private Placement | |||||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | |||||
Sale of private placement warrants (in shares) | shares | 540,000 | ||||
Proceeds from sale of private placement warrants | $ 540,000 |
DESCRIPTION OF ORGANIZATION, _3
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION-Trust Account Redemptions and Extension of Combination Period (Details) - Subsequent Events - USD ($) | Mar. 19, 2023 | Mar. 16, 2023 | Jan. 12, 2023 |
Class A Ordinary shares | |||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | |||
Number of shares elected to redeem | 13,617,502 | 1,506,480 | 12,111,022 |
Redemption price per share | $ 10.26 | $ 10.26 | |
Aggregate redemption amount | $ 139,682,935.44 | $ 15,456,484.80 | $ 124,226,450.64 |
Sponsor | Extended amendment | |||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | |||
Amount to be deposited in trust account | 101,339 | ||
Maximum limit of amount to deposit in trust account | $ 200,000 | ||
Price per share considered to deposit amount in trust account | $ 0.06 | ||
Aggregate redemption amount | $ 124,200,000 | ||
Amount available in trust account after redemption | $ 17,400,000 | ||
Number of shares outstanding | 1,688,978 | ||
Sponsor | Extended amendment | Class A Ordinary shares | |||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | |||
Number of shares elected to redeem | 12,111,022 | ||
Redemption price per share | $ 10.257 |
DESCRIPTION OF ORGANIZATION, _4
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION - Proposed Business Combination (Details) | 12 Months Ended |
Dec. 31, 2022 D $ / shares shares | |
Lock-up Agreement | |
Proposed Business Combination | |
Lock-up shares, stock price trigger | $ / shares | $ 12 |
Lock-up shares, number of trading days | D | 20 |
Lock-up shares, number of trading day period on a VWAP | 30 days |
Lock-up Agreement | 6 months after Closing | |
Proposed Business Combination | |
Lock-up shares, percentage of shares restricted | 0.33% |
Lock-up shares, restriction period (in months) | 6 months |
Lock-up Agreement | 12 months after Closing | |
Proposed Business Combination | |
Lock-up shares, percentage of shares restricted | 0.33% |
Lock-up shares, restriction period (in months) | 12 months |
Lock-up Agreement | 24 months after Closing | |
Proposed Business Combination | |
Lock-up shares, percentage of shares restricted | 0.33% |
Lock-up shares, restriction period (in months) | 24 months |
Amendment to the Insider Letter Agreement | |
Proposed Business Combination | |
Thresholder period for not to transfer of founder shares | 6 months |
Stock price trigger per share | $ / shares | $ 12 |
Threshold trading days for release of founder shares | D | 20 |
Threshold trading day period for release of founder shares | 30 days |
Threshold period after closing of business combination for release of founder shares | 150 days |
Amendment No. 2 to Forward Purchase Agreement and Related Agreements | |
Proposed Business Combination | |
Number of additional shares to be issued upon business combinations | shares | 499,993 |
DESCRIPTION OF ORGANIZATION, _5
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION - Liquidity and Capital Resources (Details) - USD ($) | 10 Months Ended | 12 Months Ended |
Dec. 31, 2021 | Dec. 31, 2022 | |
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | ||
Aggregate purchase price | $ 25,000 | |
Sponsor | ||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | ||
Aggregate purchase price | $ 25,000 | |
Proceeds from Related Party Debt | 117,000 | |
Working capital loan outstanding | $ 0 | $ 356,000 |
DESCRIPTION OF ORGANIZATION, _6
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION - Additional Information (Details) | 10 Months Ended | 12 Months Ended | ||||||
Mar. 20, 2023 USD ($) $ / shares shares | Mar. 16, 2023 USD ($) $ / shares shares | Dec. 08, 2022 USD ($) $ / shares shares | Jun. 16, 2022 USD ($) $ / shares shares | Dec. 31, 2021 USD ($) $ / shares | Dec. 31, 2022 D $ / shares shares | Mar. 19, 2023 USD ($) shares | Jan. 12, 2023 USD ($) $ / shares shares | |
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | ||||||||
Aggregate purchase price | $ | $ 25,000 | |||||||
Exercise price of warrants | $ / shares | $ 11.50 | |||||||
Hydra Promissory Note | ||||||||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | ||||||||
Principal Amount | $ | $ 8,000,000 | |||||||
Original issue discount | $ | $ 400,000 | |||||||
Interest rate | 9% | |||||||
Right to receive percentage of principal amount | 120% | |||||||
Consideration to waive acceleration right as percentage of principal amount | 125% | |||||||
Consideration to waive acceleration right | $ | $ 10,000,000 | |||||||
Term after the consummation of the Business Combination for payments of consideration to waive acceleration right | 5 days | |||||||
Ewon | Private Placement Warrants | ||||||||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | ||||||||
Number of forfeited warrants received by sponsors | 1,653,466 | |||||||
FPA Investors' | Private Placement Warrants | ||||||||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | ||||||||
Number of forfeited warrants received by sponsors | 2,480,000 | |||||||
Forward Purchase Agreement | FPA Investors' | ||||||||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | ||||||||
Monetary consideration of additional shares issued in consideration for the FPA Investors entering into the latest amendment | $ | $ 0 | |||||||
Lock-up Agreement | ||||||||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | ||||||||
Lock-up shares, stock price trigger | $ / shares | $ 12 | |||||||
Lock-up shares, number of trading days | D | 20 | |||||||
Lock-up shares, number of trading day period on a VWAP | 30 days | |||||||
Lock-up Agreement | 6 months after Closing | ||||||||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | ||||||||
Lock-up shares, percentage of shares restricted | 0.33% | |||||||
Lock-up shares, restriction period (in months) | 6 months | |||||||
Lock-up Agreement | 12 months after Closing | ||||||||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | ||||||||
Lock-up shares, percentage of shares restricted | 0.33% | |||||||
Lock-up shares, restriction period (in months) | 12 months | |||||||
Lock-up Agreement | 24 months after Closing | ||||||||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | ||||||||
Lock-up shares, percentage of shares restricted | 0.33% | |||||||
Lock-up shares, restriction period (in months) | 24 months | |||||||
Amendment to the Insider Letter Agreement | ||||||||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | ||||||||
Thresholder period for not to transfer of founder shares | 6 months | |||||||
Stock price trigger per share | $ / shares | $ 12 | |||||||
Threshold trading days for release of founder shares | D | 20 | |||||||
Threshold trading day period for release of founder shares | 30 days | |||||||
Threshold period after closing of business combination for release of founder shares | 150 days | |||||||
Lilly Lock-Up Agreement | ||||||||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | ||||||||
Lock-up shares, stock price trigger | $ / shares | $ 12 | |||||||
Lock-up shares, number of trading days | D | 20 | |||||||
Lock-up shares, number of trading day period on a VWAP | 30 days | |||||||
Lilly Lock-Up Agreement | 6 months after Closing | ||||||||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | ||||||||
Lock-up shares, percentage of shares restricted | 0.33% | |||||||
Lock-up shares, restriction period (in months) | 6 months | |||||||
Lilly Lock-Up Agreement | 12 months after Closing | ||||||||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | ||||||||
Lock-up shares, percentage of shares restricted | 1% | |||||||
Lock-up shares, restriction period (in months) | 12 months | |||||||
Lilly Lock-Up Agreement | 24 months after Closing | ||||||||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | ||||||||
Lock-up shares, percentage of shares restricted | 0.33% | |||||||
Lock-up shares, restriction period (in months) | 24 months | |||||||
Subsequent Events | Forward Purchase Agreement | FPA Investors' | ||||||||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | ||||||||
Price per share | $ / shares | $ 10 | |||||||
Number of additional shares issued in consideration for the FPA Investors entering into the latest amendment | 2,500,000 | |||||||
Class A Ordinary shares | ||||||||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | ||||||||
Ordinary shares, par value (in dollars per share) | $ / shares | $ 0.0001 | $ 0.0001 | ||||||
Number of shares outstanding | 27,552,148 | |||||||
Number of options outstanding | 1,941,933 | |||||||
Class A Ordinary shares | Private Placement Warrants | ||||||||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | ||||||||
Number of options outstanding | 5,910,000 | |||||||
Number of share for each options | 11.50 | |||||||
Class A Ordinary shares | Public Warrants | ||||||||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | ||||||||
Number of share for each warrant | 6,900,000 | |||||||
Exercise price of warrants | $ / shares | $ 11.50 | |||||||
Class A Ordinary shares | PIPE Subscription Agreement | ||||||||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | ||||||||
Price per share | $ / shares | $ 10 | |||||||
Aggregate purchase price | $ | $ 20,099,500 | |||||||
Class A Ordinary shares | Forward Purchase Agreement | FPA Investors' | ||||||||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | ||||||||
Price per share | $ / shares | $ 10 | |||||||
Class A Ordinary shares | Sponsor Forfeiture Agreement | Private Placement Warrants | ||||||||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | ||||||||
Number of warrants forfeited | 4,133,466 | |||||||
Exercise price of warrants forfeited | $ / shares | $ 11.50 | |||||||
Class A Ordinary shares | PIPE Subscription Agreement | ||||||||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | ||||||||
Number of shares issued | 2,009,950 | |||||||
Class A Ordinary shares | PIPE Subscription Agreement | Ewon | ||||||||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | ||||||||
Number of shares issued | 2,000,000 | |||||||
Class A Ordinary shares | PIPE Subscription Agreement | Eugene | ||||||||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | ||||||||
Number of shares issued | 9,950 | |||||||
Class A Ordinary shares | Business Combination Agreement | ||||||||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | ||||||||
Number of shares issued | 14,558,067 | |||||||
Class A Ordinary shares | Business Combination Agreement | Amit Munshi | ||||||||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | ||||||||
Number of shares issued | 1,941,933 | |||||||
Class A Ordinary shares | Subsequent Events | ||||||||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | ||||||||
Holders of number of shares exercised their right to redeem shares for cash | 1,506,480 | 13,617,502 | 12,111,022 | |||||
Ordinary shares, par value (in dollars per share) | $ / shares | $ 0.0001 | |||||||
Redemption price per share | $ / shares | $ 10.26 | $ 10.26 | ||||||
Aggregate redemption amount | $ | $ 15,456,484.80 | $ 139,682,935.44 | $ 124,226,450.64 | |||||
Class A Ordinary shares | Subsequent Events | Forward Purchase Agreement | FPA Investors' | ||||||||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | ||||||||
Price per share | $ / shares | $ 10 | |||||||
Aggregate purchase price | $ | $ 30,000,000 | |||||||
Number of shares issued as public share redemptions were greater than 90% at the time of the Business Combination | 1,301,633 | |||||||
Aggregate value of shares issued as public share redemptions were greater than 90% at the time of the Business Combination | $ | $ 13,016,330 | |||||||
Number of shares issued | 3,000,000 | |||||||
Class A Ordinary shares | Subsequent Events | Holdco | ||||||||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | ||||||||
Ordinary shares, par value (in dollars per share) | $ / shares | $ 0.0001 | |||||||
Merger Consideration | $ | $ 165,000,000 | |||||||
Class A Ordinary Shares underlying restricted stock units | ||||||||
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | ||||||||
Number of warrants to purchase shares issued | 499,993 |
SUMMARY OF SIGNIFICANT ACCOUN_4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | ||
Cash equivalents | $ 0 | $ 0 |
Unrecognized tax benefits | 0 | 0 |
Unrecognized tax benefits accrued for interest and penalties | $ 0 | $ 0 |
Anti-dilutive securities attributable to warrants (in shares) | 450,000 | |
Private Placement | ||
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | ||
Anti-dilutive securities attributable to warrants (in shares) | 12,810,000 | |
Class A ordinary shares subject to possible redemption | ||
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | ||
Class A ordinary shares subject to possible redemption, shares outstanding | 13,800,000 | 13,800,000 |
SUMMARY OF SIGNIFICANT ACCOUN_5
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Compute Basic and Diluted Net Income (Loss) Per Share (Details) - USD ($) | 10 Months Ended | 12 Months Ended |
Dec. 31, 2021 | Dec. 31, 2022 | |
Class A Ordinary shares | ||
Numerator: | ||
Allocation of net income (loss) - basic | $ 4,893,422 | $ 2,839,302 |
Allocation of net income (loss) - diluted | $ 4,814,256 | $ 2,839,302 |
Weighted average number of shares outstanding | ||
Basic weighted average ordinary shares outstanding | 7,834,343 | 13,800,000 |
Diluted weighted average common shares outstanding | 7,834,343 | 13,800,000 |
Basic net income per ordinary shares | $ 0.62 | $ 0.21 |
Diluted net income per ordinary share | $ 0.61 | $ 0.21 |
Class B Ordinary shares | ||
Numerator: | ||
Allocation of net income (loss) - basic | $ 1,955,233 | $ 709,825 |
Allocation of net income (loss) - diluted | $ 2,034,389 | $ 709,825 |
Weighted average number of shares outstanding | ||
Basic weighted average ordinary shares outstanding | 3,130,303 | 3,450,000 |
Diluted weighted average common shares outstanding | 3,310,606 | 3,450,000 |
Basic net income per ordinary shares | $ 0.62 | $ 0.21 |
Diluted net income per ordinary share | $ 0.61 | $ 0.21 |
INITIAL PUBLIC OFFERING (Detail
INITIAL PUBLIC OFFERING (Details) - USD ($) | 10 Months Ended | ||||
Jul. 19, 2021 | Jul. 16, 2021 | Dec. 31, 2021 | Dec. 31, 2022 | Dec. 08, 2022 | |
Initial Public Offering | |||||
Offering costs | $ 3,090,250 | ||||
Deferred underwriting commissions | $ 4,010,000 | $ 4,010,000 | |||
Exercise price of warrants | $ 11.50 | ||||
Public Warrants | Class A Ordinary shares | |||||
Initial Public Offering | |||||
Number of shares issuable per warrant | 6,900,000 | ||||
Exercise price of warrants | $ 11.50 | ||||
IPO | |||||
Initial Public Offering | |||||
Number of units sold | 1,800,000 | 12,000,000 | |||
Price per share | $ 10 | ||||
Proceeds received from initial public offering gross | $ 18,000,000 | $ 120,000,000 | |||
Offering costs | 990,000 | 10,500,000 | |||
Reimbursement of offering costs from underwriters | 480,000 | 480,000 | |||
Deferred underwriting commissions | 630,000 | 3,400,000 | |||
Offering costs allocated to derivate warrant liabilities | $ 62,000 | ||||
IPO | Anchor Investors | |||||
Initial Public Offering | |||||
Offering costs | 4,700,000 | ||||
Deferred underwriting commissions | 3,400,000 | ||||
Offering costs allocated to derivate warrant liabilities | $ 685,000 | ||||
IPO | Public Warrants | Class A Ordinary shares | |||||
Initial Public Offering | |||||
Number of shares in a unit | 1 | ||||
Number of warrants in a unit | 0.50 | ||||
Number of shares issuable per warrant | 1 | ||||
Exercise price of warrants | $ 11.50 |
RELATED PARTY TRANSACTIONS - Fo
RELATED PARTY TRANSACTIONS - Founder Shares (Details) | 10 Months Ended | 12 Months Ended | |||||
Jul. 19, 2021 shares | Jun. 14, 2021 shares | Mar. 22, 2021 USD ($) $ / shares shares | Dec. 31, 2021 USD ($) shares | Dec. 31, 2022 USD ($) item $ / shares shares | Jul. 16, 2021 $ / shares | Jun. 13, 2021 shares | |
Related Party Transaction [Line Items] | |||||||
Aggregate purchase price | $ | $ 25,000 | ||||||
Restrictions on transfer period of time after business combination completion | 1 year | ||||||
Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share) | $ / shares | $ 12 | ||||||
Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination | item | 20 | ||||||
Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination | item | 30 | ||||||
Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences | 150 days | ||||||
IPO | |||||||
Related Party Transaction [Line Items] | |||||||
Price per share | $ / shares | $ 10 | ||||||
Class B Ordinary shares | |||||||
Related Party Transaction [Line Items] | |||||||
Number of shares outstanding | 3,450,000 | 3,450,000 | |||||
Sponsor | |||||||
Related Party Transaction [Line Items] | |||||||
Aggregate purchase price | $ | $ 25,000 | ||||||
Sponsor | Class B Ordinary shares | |||||||
Related Party Transaction [Line Items] | |||||||
Number of shares issued | 4,312,500 | ||||||
Aggregate purchase price | $ | $ 25,000 | ||||||
Price per share | $ / shares | $ 0.006 | ||||||
Number of shares cancelled | 450,000 | ||||||
Number of surrendered | 862,500 | ||||||
Number of shares outstanding | 3,450,000 | 4,312,500 | |||||
Shares not subjected to possible redemption | 450,000 | ||||||
Percentage of issued and outstanding shares after the Initial Public Offering collectively held by initial stockholders | 20% | ||||||
Sponsor | Class B Ordinary shares | Minimum | |||||||
Related Party Transaction [Line Items] | |||||||
Number of shares outstanding | 4,312,500 | ||||||
Sponsor | Class B Ordinary shares | Maximum | |||||||
Related Party Transaction [Line Items] | |||||||
Number of shares outstanding | 3,450,000 | ||||||
Anchor Investors | IPO | |||||||
Related Party Transaction [Line Items] | |||||||
Fair value of membership interests | $ | $ 7,200,000 | ||||||
Anchor Investors | Sponsor | IPO | |||||||
Related Party Transaction [Line Items] | |||||||
Indirect economic interest (in shares) | 917,365 | ||||||
Share Price | $ / shares | $ 0.008 | ||||||
Fair value of membership interests | $ | $ 2,500,000 | ||||||
Anchor Investors | Sponsor | Private Placement | IPO | |||||||
Related Party Transaction [Line Items] | |||||||
Indirect economic interest (in shares) | 2,490,500 | ||||||
Share Price | $ / shares | $ 1 |
RELATED PARTY TRANSACTIONS - Pr
RELATED PARTY TRANSACTIONS - Private Placement (Details) - USD ($) | Jul. 19, 2021 | Jul. 16, 2021 | Dec. 31, 2022 |
Related Party Transaction [Line Items] | |||
Exercise price of warrants | $ 11.50 | ||
Private Placement | Class A Ordinary shares | |||
Related Party Transaction [Line Items] | |||
Number of shares issuable per warrant | 1 | ||
Exercise price of warrants | $ 11.50 | ||
Private Placement | Sponsor | |||
Related Party Transaction [Line Items] | |||
Number of warrants to purchase shares issued | 540,000 | 5,370,000 | |
Price of warrant | $ 1 | ||
Proceeds from sale of private placement warrants | $ 540,000 | $ 5,400,000 | |
Private Placement and Second Private Placement | |||
Related Party Transaction [Line Items] | |||
Number of warrants to purchase shares issued | 2,490,500 |
RELATED PARTY TRANSACTIONS - Ad
RELATED PARTY TRANSACTIONS - Additional Information (Details) - USD ($) | 1 Months Ended | 9 Months Ended | 10 Months Ended | 12 Months Ended | |||||
Jun. 30, 2021 | Mar. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2022 | Dec. 31, 2021 | Nov. 02, 2022 | May 11, 2022 | Mar. 22, 2021 | |
Related Party Transaction [Line Items] | |||||||||
General and administrative expenses - Related Party | $ 167,849 | $ 381,102 | |||||||
Warrant conversion price | $ 11.50 | ||||||||
Sponsor | |||||||||
Related Party Transaction [Line Items] | |||||||||
Proceeds from Related Party Debt | $ 117,000 | ||||||||
Working capital loan outstanding | $ 0 | 0 | 356,000 | $ 0 | |||||
Promissory Note with Related Party | |||||||||
Related Party Transaction [Line Items] | |||||||||
Maximum borrowing capacity of related party promissory note | $ 200,000 | ||||||||
Outstanding balance of related party note | 0 | ||||||||
Proceeds from Related Party Debt | $ 117,000 | ||||||||
Promissory Note with Related Party | Minimum | Sponsor | |||||||||
Related Party Transaction [Line Items] | |||||||||
Loan, principal amount | $ 500,000 | $ 300,000 | |||||||
Promissory Note with Related Party | Warrants | Sponsor | |||||||||
Related Party Transaction [Line Items] | |||||||||
Price per share | $ 1 | $ 1 | |||||||
Administrative Support Agreement | |||||||||
Related Party Transaction [Line Items] | |||||||||
General and administrative expenses - Related Party | 55,000 | 120,000 | |||||||
Related Party Loans | Working capital loans | |||||||||
Related Party Transaction [Line Items] | |||||||||
Working capital loan outstanding | 0 | 0 | 356,000 | 0 | |||||
Loan conversion agreement warrant | $ 1,500,000 | ||||||||
Price of warrants | $ 1 | ||||||||
Support Agreement and Services | |||||||||
Related Party Transaction [Line Items] | |||||||||
Expenses incurred and paid | $ 78,000 | $ 18,000 | |||||||
General and administrative expenses - Related Party | $ 0 | 201,000 | |||||||
Support Agreement and Services | Sponsor | |||||||||
Related Party Transaction [Line Items] | |||||||||
Expenses per month | 10,000 | ||||||||
General and administrative expenses - Related Party | $ 113,000 | $ 113,000 | $ 60,000 |
RELATED PARTY TRANSACTIONS - _2
RELATED PARTY TRANSACTIONS - Forward Purchase Agreements (Details) - USD ($) | 1 Months Ended | 10 Months Ended | |
Aug. 05, 2021 | Jan. 31, 2022 | Dec. 31, 2021 | |
Related Party Transaction [Line Items] | |||
Aggregate purchase price | $ 25,000 | ||
Forward Purchase Agreements | |||
Related Party Transaction [Line Items] | |||
Number of shares issued | 7,500,000 | ||
Aggregate purchase price | $ 75,000,000 | ||
Price per share | $ 10 | ||
Amended Forward Purchase Agreements | |||
Related Party Transaction [Line Items] | |||
Purchase of binding redemption backstop | $ 15,000,000 | ||
Minimum shareholders redemptions with business combination | 90% | ||
Bridge financing by convertible promissory note | $ 30,000,000 | ||
Amended Forward Purchase Agreements | Minimum | |||
Related Party Transaction [Line Items] | |||
Number of shares issued | 3,000,000 | ||
Aggregate purchase price | $ 30,000,000 | ||
Amended Forward Purchase Agreements | Maximum | |||
Related Party Transaction [Line Items] | |||
Number of shares issued | 7,500,000 | ||
Aggregate purchase price | $ 75,000,000 |
COMMITMENTS AND CONTINGENCIES (
COMMITMENTS AND CONTINGENCIES (Details) | Jul. 19, 2021 USD ($) $ / shares shares | Jul. 16, 2021 USD ($) shares | Dec. 31, 2022 USD ($) item | Dec. 31, 2021 USD ($) |
COMMITMENTS AND CONTINGENCIES | ||||
Underwriting agreement options granted period | 45 days | |||
Deferred underwriting commissions | $ 4,010,000 | $ 4,010,000 | ||
Maximum number of demands for registration of securities | item | 3 | |||
Over-Allotment option | ||||
COMMITMENTS AND CONTINGENCIES | ||||
Number of units sold | shares | 1,800,000 | |||
Deferred underwriting commissions | $ 630,000 | |||
Additional underwriter fee paid | $ 360,000 | |||
IPO | ||||
COMMITMENTS AND CONTINGENCIES | ||||
Number of units sold | shares | 1,800,000 | 12,000,000 | ||
Underwriting cash discount per unit | $ / shares | $ 0.20 | |||
Aggregate underwriter cash discount | $ 2,400,000 | |||
Reimbursement of offering costs from underwriters | $ 480,000 | $ 480,000 | ||
Deferred underwriting commissions per unit | $ / shares | $ 0.35 | |||
Deferred underwriting commissions | $ 630,000 | $ 3,400,000 | ||
Reimbursement of deferred commissions from underwriter | $ 820,000 |
CLASS A ORDINARY SHARES SUBJE_3
CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION (Details) | 10 Months Ended | 12 Months Ended | |
Dec. 31, 2021 USD ($) shares | Dec. 31, 2022 USD ($) Vote $ / shares shares | Dec. 31, 2021 USD ($) shares | |
CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION | |||
Gross proceeds | $ 138,000,000 | ||
Proceeds allocated to Public Warrants | (8,625,000) | ||
Class A ordinary share issuance costs, net of reimbursement from underwriter | (9,150,115) | ||
Accretion of carrying value to redemption value | $ 20,792,717 | 19,155,115 | |
Increase in redemption value of Class A common stock subject to possible redemption | $ 1,994,352 | ||
Class A common stock subject to possible redemption | $ 139,380,000 | $ 141,374,352 | $ 139,380,000 |
Class A Ordinary shares | |||
CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION | |||
Number of shares authorized | shares | 200,000,000 | ||
Temporary equity par value | $ / shares | $ 0.0001 | ||
Number of votes for each share | Vote | 1 | ||
Class A ordinary shares subject to possible redemption, shares outstanding | shares | 13,800,000 | ||
Class A ordinary shares subject to possible redemption | |||
CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION | |||
Temporary equity shares issued | shares | 13,800,000 | 13,800,000 | 13,800,000 |
Class A ordinary shares subject to possible redemption, shares outstanding | shares | 13,800,000 | 13,800,000 | 13,800,000 |
Class A common stock subject to possible redemption | $ 139,380,000 | $ 141,374,352 | $ 139,380,000 |
SHAREHOLDERS' DEFICIT - Preferr
SHAREHOLDERS' DEFICIT - Preferred Stock Shares (Details) - $ / shares | Dec. 31, 2022 | Dec. 31, 2021 |
SHAREHOLDERS' DEFICIT | ||
Preference shares, shares authorized | 1,000,000 | 1,000,000 |
Preferred stock, par value, (in dollars per share) | $ 0.0001 | $ 0.0001 |
Preference shares, shares issued | 0 | 0 |
Preference shares, shares outstanding | 0 | 0 |
SHAREHOLDERS' DEFICIT - Common
SHAREHOLDERS' DEFICIT - Common Stock Shares (Details) | 12 Months Ended | ||||||
Jul. 19, 2021 shares | Jun. 14, 2021 shares | Dec. 31, 2022 Vote $ / shares shares | Dec. 08, 2022 shares | Dec. 31, 2021 $ / shares shares | Jun. 13, 2021 shares | Mar. 23, 2021 shares | |
SHAREHOLDERS' DEFICIT | |||||||
Common shares, number of votes per share | Vote | 1 | ||||||
Class A Ordinary shares | |||||||
SHAREHOLDERS' DEFICIT | |||||||
Common shares, shares authorized (in shares) | 200,000,000 | 200,000,000 | |||||
Common shares, par value (in dollars per share) | $ / shares | $ 0.0001 | $ 0.0001 | |||||
Common shares, number of votes per share | Vote | 1 | ||||||
Class A common stock subject to possible redemption, outstanding (in shares) | 13,800,000 | ||||||
Common shares, shares outstanding (in shares) | 27,552,148 | ||||||
Class A Common Stock Subject to Redemption | |||||||
SHAREHOLDERS' DEFICIT | |||||||
Class A common stock subject to possible redemption, issued (in shares) | 13,800,000 | 13,800,000 | |||||
Class A common stock subject to possible redemption, outstanding (in shares) | 13,800,000 | 13,800,000 | |||||
Class B Ordinary shares | |||||||
SHAREHOLDERS' DEFICIT | |||||||
Common shares, shares authorized (in shares) | 20,000,000 | 20,000,000 | |||||
Common shares, par value (in dollars per share) | $ / shares | $ 0.0001 | $ 0.0001 | |||||
Common shares, shares issued (in shares) | 3,450,000 | 3,450,000 | 4,312,500 | ||||
Common shares, shares outstanding (in shares) | 3,450,000 | 3,450,000 | |||||
Shares not subjected to forfeiture | 450,000 | ||||||
Ratio to be applied to the stock in the conversion | 20 | ||||||
Class B Ordinary shares | Sponsor | |||||||
SHAREHOLDERS' DEFICIT | |||||||
Common shares, shares outstanding (in shares) | 3,450,000 | 4,312,500 | |||||
Number of surrendered | 862,500 | ||||||
Number of shares cancelled | 450,000 | ||||||
Percentage of issued and outstanding shares after the Initial Public Offering collectively held by initial stockholders | 20% |
DERIVATIVE WARRANT LIABILITIES
DERIVATIVE WARRANT LIABILITIES (Details) | 12 Months Ended | |||
Dec. 31, 2022 item D $ / shares shares | Dec. 08, 2022 $ / shares | Dec. 31, 2021 shares | Jul. 19, 2021 $ / shares | |
DERIVATIVE WARRANT LIABILITIES | ||||
Warrants exercisable term from the completion of business combination | 30 days | |||
Warrants exercisable term from the closing of the public offering | 12 months | |||
Threshold period for filling registration statement after business combination | 45 days | |||
Exercise price of warrants | $ 11.50 | |||
Public Warrants expiration term | 5 years | |||
Percentage of gross proceeds on total equity proceeds | 60% | |||
Adjustment of exercise price of warrants based on market value (as a percent) | 115% | |||
Percentage of adjustment of redemption price of stock based on market value | 180% | |||
Redemption of Warrant Price Per Share Equals or Exceeds18.00 | ||||
DERIVATIVE WARRANT LIABILITIES | ||||
Stock price trigger for redemption of public warrants | $ 18 | |||
Redemption price per public warrant (in dollars per share) | $ 0.01 | |||
Minimum threshold written notice period for redemption of public warrants | 30 days | |||
Threshold trading days for redemption of public warrants | 20 days | |||
Threshold number of business days before sending notice of redemption to warrant holders | item | 30 | |||
Redemption period | 30 days | |||
Redemption of Warrant Price Per Share Equals or Exceeds10.00 | ||||
DERIVATIVE WARRANT LIABILITIES | ||||
Stock price trigger for redemption of public warrants | $ 10 | |||
Class A Ordinary shares | ||||
DERIVATIVE WARRANT LIABILITIES | ||||
Threshold period for filling registration statement within number of days of business combination | 60 days | |||
Threshold issue price per share | $ 9.20 | |||
Threshold period for not to transfer, assign or sell any of their shares or warrants after the completion of the initial business combination | 30 days | |||
Number of trading days on which fair market value of shares is reported | D | 10 | |||
Class A Ordinary shares | Public Warrants | ||||
DERIVATIVE WARRANT LIABILITIES | ||||
Exercise price of warrants | $ 11.50 | |||
IPO | ||||
DERIVATIVE WARRANT LIABILITIES | ||||
Warrants outstanding | shares | 12,810,000 | 12,810,000 | ||
IPO | Public Warrants | ||||
DERIVATIVE WARRANT LIABILITIES | ||||
Warrants outstanding | shares | 6,900,000 | 6,900,000 | ||
IPO | Private Placement Warrants | ||||
DERIVATIVE WARRANT LIABILITIES | ||||
Warrants outstanding | shares | 5,910,000 | 5,910,000 | ||
IPO | Class A Ordinary shares | Public Warrants | ||||
DERIVATIVE WARRANT LIABILITIES | ||||
Exercise price of warrants | $ 11.50 |
FAIR VALUE MEASUREMENTS - Sched
FAIR VALUE MEASUREMENTS - Schedule of company's financial assets and liabilities that are measured at fair value on a recurring basis (Details) - USD ($) | Dec. 31, 2022 | Dec. 31, 2021 |
Assets: | ||
Investments held in Trust Account | $ 141,474,352 | $ 139,399,054 |
Liabilities: | ||
Derivative warrant liabilities | 1,921,500 | 6,069,900 |
Level 1 | Recurring | Public Warrants | ||
Liabilities: | ||
Derivative warrant liabilities | 1,035,000 | 3,174,000 |
Level 1 | Recurring | Private Warrants | ||
Liabilities: | ||
Derivative warrant liabilities | 0 | 0 |
Level 1 | U.S. Treasury Securities | Recurring | ||
Assets: | ||
Investments held in Trust Account | 141,474,352 | 139,399,054 |
Level 2 | Recurring | Public Warrants | ||
Liabilities: | ||
Derivative warrant liabilities | 0 | 0 |
Level 2 | Recurring | Private Warrants | ||
Liabilities: | ||
Derivative warrant liabilities | 0 | 0 |
Level 2 | U.S. Treasury Securities | Recurring | ||
Assets: | ||
Investments held in Trust Account | 0 | 0 |
Level 3 | Recurring | Public Warrants | ||
Liabilities: | ||
Derivative warrant liabilities | 0 | 0 |
Level 3 | Recurring | Private Warrants | ||
Liabilities: | ||
Derivative warrant liabilities | 886,500 | 2,895,900 |
Level 3 | U.S. Treasury Securities | Recurring | ||
Assets: | ||
Investments held in Trust Account | $ 0 | $ 0 |
FAIR VALUE MEASUREMENTS - Sch_2
FAIR VALUE MEASUREMENTS - Schedule of quantitative information regarding Level 3 fair value measurements inputs (Details) - Level 3 - $ / shares | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2022 | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Exercise price | $ 11.50 | $ 11.50 |
Stock price | $ 9.87 | $ 10.21 |
Volatility | 9.50% | 1% |
Term (years) | 6 months 14 days | 4 years 5 months 15 days |
Risk-free rate | 1.43% | 4.05% |
Dividend yield | 0% | 0% |
FAIR VALUE MEASUREMENTS - Sch_3
FAIR VALUE MEASUREMENTS - Schedule of change in the fair value of warrants measured with Level 3 inputs (Details) - USD ($) | 10 Months Ended | 12 Months Ended |
Dec. 31, 2021 | Dec. 31, 2022 | |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||
Change in fair value of derivative warrant liabilities | $ 10,238,100 | $ 4,148,400 |
Level 3 | ||
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||
Derivative warrant liabilities beginning Balance | 2,895,900 | |
Issuance of Public and Private Warrants | 16,308,000 | |
Transfer of Public Warrants to Level 1 measurement | 8,625,000 | |
Change in fair value of derivative warrant liabilities | (4,787,100) | (2,009,400) |
Derivative warrant liabilities end Balance | $ 2,895,900 | $ 886,500 |